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CHAPTER I 
 
 
INTRODUCTION TO GENE-ENVIRONMENT INTERACTIONS: PARKINSON’S 
DISEASE AND MANGANESE TOXICITY 
 
 
 
Parkinson’s Disease 
 
Introduction 
Parkinson’s Disease (PD) is one of the most common neurodegenerative disorders in 
the U.S. population, with a median age of onset around 60 years1. This disease affects 
more than 1% of the population over the age of 60 by causing preferential damage to 
the nigrostriatal circuit of the brain. More specifically, distinct degeneration of 
dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNpc) is the 
prominent pathological hallmark of the disease, along with the presence of α-synuclein-
rich Lewy body inclusions. These features ultimately lead to motor dysfunction, with 
cardinal symptoms including bradykinesia (slowness in movement), tremors, rigidity, 
and postural instability2. Cognitive deficits and emotional and behavioral problems are 
also seen in diseased individuals. Later stages of the disease are often marked by 
appearance of a masked face, along with a forward-flexed posture, gait freezing, 
shuffling steps, and gastrointestinal issues1.  
The Dopaminergic System  
While the selectivity in PD-associated cell death remains poorly understood, it is 
advantageous to understand how the DAergic system operates in cells. The 
neurotransmitter dopamine (3,4-dihydroxyphenethylamine, DA) is synthesized in a two-
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step process, starting with hydroxylation of the amino acid tyrosine via the rate-limiting 
enzyme tyrosine hydroxylase (TH) to produce L-DOPA (L-dihydroxyphenylalanine)3. DA 
is then produced from L-DOPA via decarboxylation by AADC (aromatic acid 
decarboxylase)4. Upon synthesis, DA is packaged into synaptic vesicles by the 
vesicular monoamine transporter 2 (VMAT2) for release into the synaptic cleft5. DA itself 
can be metabolized by monoamine oxidase (MAO) into the metabolite DOPAC (3,4-
dihydroxyphenylacetic acid), or by catechol-O-methyl transferase (COMT) into 3-MT (3-
methoxytyramine)6, 7. In addition to metabolism, free dopamine is typically cleared from 
the synaptic cleft by the dopamine transporter (DAT), localized to axon terminals, that 
helps recycle the neurotransmitter for future storage and release. This 12-
transmembrane domain transporter is a symporter, with dopamine reuptake coupled to 
the co-transport of two Na+ ions and one Cl- ion8, 9.  
There are four major DAergic neural circuits in the brain: the tuberoinfundibular10, 
mesocortical11, mesolimbic12 and nigrostriatal pathways13, with the last circuit implicated 
in PD. The DAergic neurons of the nigrostriatal pathway send their projections from the 
SNpc to the striatum, which in primates, consists of the caudate nucleus and putamen14. 
This circuit is a vital component of the basal ganglia region implicated in PD, which is 
comprised of the SN, striatum, globus pallidus and subthalamic nucleus (STN), and 
interacts with the motor cortex and thalamus. The ultimate functional output of the 
striatum involves the coordination of movement15. This system uses two antagonistic 
circuits to maintain balance: the direct and indirect pathways16 (Fig 1). The direct 
pathway starts with excitatory, glutamatergic input from the motor cortex to stimulate the 
striatum, which is mostly composed of inhibitory, GABAergic medium spiny neurons  
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Figure 1. Schematic illustrating the basal ganglia circuitry involved in both direct and indirect 
pathways. DA: dopamine; Glu: glutamate; GPe: globus pallius external segment; GPi: globus 
pallidus internal segment; SNpc: substantia nigra pars compacta; SNpr: substantia nigra pars 
reticulate; STN: subthalamic nucleus.   
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(MSNs), resulting in inhibition of the inhibitory cells of the globus pallidus internal 
segment (GPi) and the substantia nigra pars reticulate (SNpr). This disinhibition results 
in increased stimulation of the excitatory neurons of the thalamus, resulting in increased 
excitation of the motor cortex to produce a hyperkinetic response17. Meanwhile, the 
indirect pathway starts with similar input from the motor cortex to stimulate the striatum, 
which then inhibits the inhibitory cells of the globus pallidus external segment (GPe) and 
SNpr from inhibiting the excitatory cells of the STN. This results in stimulation of the 
GPi/SNpr, resulting in inhibition of the thalamus to decrease stimulation of the motor 
cortex to produce a hypokinetic response. Additionally, the SNpc modulates this 
antagonistic circuitry through DAergic stimulation of the striatum17.  
 The intricacies of this pathway revolve around DA’s modulatory effects on its 
receptors. There are 5 different DA receptors subdivided into two families: D1-like (D1 
and D5) and D2-like (D2, D3 and D4) receptors. These receptors are G-protein coupled 
receptors (GPCRs) that differ in their downstream targets and biochemical properties18. 
D1-like receptors are coupled to Gα-Syn proteins and activate the enzyme adenylate 
cyclase (AC) to stimulate cyclic AMP (cAMP) production for a net excitatory effect; D2-
like receptors are coupled to Gαi/o proteins and inhibit AC to prevent cAMP production 
for a net inhibitory effect19, 20 (Fig 1). Interestingly, D2 and D3 receptors offer a further 
level of DA regulation, as they can also be found as presynaptic autoreceptors that 
participate in a negative feedback loop to sense extracellular dopamine and help inhibit 
further synthesis or release21. In relationship to the basal ganglia circuitry, D1-like 
receptors are expressed by MSNs of the direct pathway, while D2-like receptors are 
expressed by MSNs of the indirect pathway22. Dopamine stimulates D1-like receptors at 
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the striatum to increase thalamic excitation of the cortex via the direct pathway, while it 
inhibits the striatum through D2-like receptors via the indirect pathway to decrease 
inhibition of thalamic excitation of the cortex (Fig 1). Thus, in the case of PD, the loss of 
DAergic input to the striatum affects both pathways to decrease thalamic excitation of 
the motor cortex, resulting in the characteristic hypokinetic responses of the disease. 
PD Pathophysiology: Molecular Mechanisms 
Upon understanding the role of the SNpc in the neural movement circuitry, it is 
apparent that the loss of DAergic innervation to the striatum would result in the opposite 
outcome of the direct pathway to produce the characteristic hypokinetic response seen 
in PD. However, the molecular mechanisms behind PD pathophysiology are still not 
fully understood. Currently known cellular processes that may be behind the 
neurodegeneration include aberrant protein folding and aggregation; mitochondrial 
dysfunction and increased oxidative stress; and proteasomal impairments23. In terms of 
PD-associated protein aggregation, the best example is the role of the protein alpha-
synuclein (α-Syn). Aggregation of this protein into cellular inclusions known as Lewy 
bodies is considered to be a pathological hallmark of PD24. Yet, the physiological role of 
α-Syn is still not fully understood. Studies have linked α-Syn to presynaptic vesicle 
formation and recycling, as well as decreased vesicular DA release that may be related 
to its ability to bind phospholipids and vesicular fusion machinery25-27. α-Syn 
aggregation has also been shown to affect TH and AADC activity, implicating impaired 
dopamine biosynthesis as a potential mechanism behind its toxicity28, 29. Additionally, α-
Syn has been shown to interact with and modulate DAT, though it remains unclear 
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whether this results in enhanced DA reuptake via increasing DAT clustering30, or 
through an attenuation of its activity31.  
  Mitochondrial dysfunction and oxidative stress also play a major role in PD 
pathophysiology. Several studies have implicated impaired Complex I activity in the 
electron transport chain (ETC) and impaired mitochondrial protease activity in PD 
patients32, 33. Moreover, downregulation of genes encoding vital mitochondrial proteins 
have been evident in DAergic neurons from patients suffering with PD34. Changes in 
mitochondrial organization have also been associated with PD.  The importance of 
mitochondrial integrity has specifically come under investigation, as two PD-associated 
proteins, PINK1 and Parkin, have recently been identified as key modulators of 
mitophagy, and will also be discussed later in this section. This process involves the 
degradation of damaged mitochondria that require mitochondrial PINK1 to recruit 
cytoplasmic Parkin, an E3 ubiquitin ligase, to facilitate the turnover35. Moreover, these 
proteins also interact with mitochondrial fusion and fission factors, such as mitofusin 2 
(Mfn2) and Drp1, to maintain a proper balance in mitochondrial network integrity36, 37. 
Thus, in the absence of either of these proteins in their functional form, aggregation of 
damaged mitochondria, and/or an imbalance between mitochondrial fusion and fission, 
can result in cell death.  
Outside of direct mitochondrial deficits in PD, overall oxidative stress is also 
evident. Oxidative stress can be viewed as an imbalance between the production of 
reactive oxygen and nitrogen species (RONS) and the cellular antioxidant defense 
mechanisms against RONS. A key factor in tilting the balance towards enhanced RONS 
levels is dopamine itself, a strong auto-oxidant that can produce damaging quinones 
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and free radicals to promote cell death38. Toxins, metals and oxygen itself can further 
catalyze the formation of these reactive intermediates, as redox-active metals can 
enhance the natural redox cycling of quinones to further generate excess free radicals. 
DA quinones can promote cellular damage by conjugating with cysteine residues of 
proteins, resulting in alterations in protein function, such as that seen with tyrosine 
hydroxylase and α-Syn39, 40. Quinone formation has also been associated with 
decreased mitochondrial function41. Antioxidants like glutathione (GSH) can counteract 
these damaging effects by acting as a quinone quencher42. GSH is a tripeptide 
composed of glutamate, glycine and cysteine, with the reactive thiol group in the 
cysteine residue acting as the RONS scavenger43. A decreased ratio of reduced forms 
vs. oxidized forms (GSH/GSSG) is often used as a measure of increased oxidative 
stress, with decreased levels of reduced GSH found in the SN of PD brains44. As this 
system also depends on a physiological balance, both GSH depletion and GSH 
overproduction can result in DAergic cell death, with the latter most likely representing a 
compensatory mechanism to protect against further cell death.  
Connecting these pathophysiological perturbations in PD are impairments in 
proteasomal or autophagic function, resulting in protein or organellar accumulation, 
respectively. The ubiquitin proteasome system (UPS) is a key system in mediating the 
process of protein degradation45. This process begins with poly-ubiquitination of 
substrate proteins by ubiquitin-conjugating enzymes, followed by degradation of the 
tagged proteins in the 26S proteasome46. Proteasomal enzymatic activity has been 
shown to be impaired in the SN of idiopathic PD patients47. Furthermore, as age is a 
significant risk factor for neurodegenerative diseases like PD, it has also been shown 
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that aging is associated with alterations in the proteasome system48. One of the 
enzymes involved in the UPS is Parkin, which also happens to be a major genetic risk 
factor for an early-onset, autosomal recessive form of PD. Interestingly, patients with 
parkin mutations do not show the characteristic Lewy body pathology49, suggesting that 
Parkin may play a role in their formation. Parkin has been shown to ubiquitinate a 
glycosylated form of α-Syn50 that may also involve targeting the protein synphillin-1, an 
α-Syn-interacting protein51.  As aforementioned, in addition to protein degradation, 
Parkin also mediates organelle turnover by participating in mitophagy. Thus, the loss of 
parkin can be majorly detrimental to the cell, as both abnormal protein and 
mitochondrial buildup can result in cell death.  
PD Models 
 Currently, several types of models exist to understand how the mechanisms 
behind PD may result in DAergic cell death. Both pharmacological and genetic tools 
have been used to explore the disease, with attempts to recapitulate the major features 
of the disease, including DAergic cell death and/or motor deficits. 
Pharmacological Models 
MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its metabolite MPP+ 
(1-methyl-4-phenylpyridinium ion) are well-known neurotoxins used to model PD. The 
discovery of MPTP as a PD model arose accidentally, as illicit Californian drug users in 
the 1980s were diagnosed with Parkinsonism after using a contaminated batch of 
MPPP, a synthetic drug that mimics effects of morphine and meperidine. Researchers 
later identified MPTP in the drug as the culprit behind the Parkinsonism52. MPTP was 
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later confirmed to produce Parkinsonism in monkeys exposed to MPTP in addition to 
SN-selective cell death53. MPTP is converted into MPP+ by MAO-B and then taken up 
by DAT into DAergic neurons, where it inhibits mitochondrial Complex I activity. MPTP 
administration in primates results in Parkinsonism that responds to L-DOPA and shows 
all cardinal motor symptoms of PD. Similar results have been achieved in studies using 
mice. However, MPTP-induced lesions of the SNpc do not present with the formation of 
Lewy bodies.   
6-OHDA:  This model utilizes 6-hydroxydopamine (6-OHDA), or oxidopamine, to result 
in degeneration of the nigrostriatal pathway, and represents the first-ever 
pharmacological PD model54. Administration of this DA analog must be done locally 
through intracranial injections, as 6-OHDA does not pass the blood brain barrier (BBB) 
and can unselectively affect all catecholaminergic neurons55. Once in the brain, 6-
OHDA acts as a hydroxylated DA analog and is taken up into DAergic neurons via 
DAT56. 6-OHDA is of particular interest in PD due to its endogenous nature as a toxic 
DA metabolite that is produced from a non-enzymatic reaction between DA, hydrogen 
peroxide and free iron at physiological concentrations57. Moreover, in vivo production of 
6-OHDA is more likely to occur in the highly oxidizing environment of DA neurons, as 6-
OHDA auto-oxidation increases production of hydrogen peroxide and free radicals, 
including the superoxide ion and hydroxyl radical58. These RONS are most likely 
generated through 6-OHDA metabolism or direct inhibition of complex I and IV of the 
mitochondrial ETC59, 60, and result in PD-associated molecular signatures, including 
increased lipid peroxidation, protein denaturation and increased GSH58.  
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Pesticides: Exposure to pesticides has long been associated as environmental risk 
factors for the development of PD. One such pesticide is rotenone, a plant flavonoid that 
is used as a broad-spectrum pesticide. Rotenone is able to easily cross the BBB and 
does not require DAT to enter DAergic neurons61, where it inhibits complex I of the 
ETC62, resulting in the production of RONS. Unlike the other toxin models, rotenone 
exposure does exhibit α-Syn Lewy body inclusions, as well as degeneration of DAergic 
cells in the nigrostriatal pathway that results in PD-like motor deficits63. However, some 
doubts have been cast on the selectivity of rotenone-induced cell death towards 
nigrostriatal DAergic neurons64, 65. Another pesticide used as a toxin model of PD is 
paraquat, a non-selective herbicide that shares structural similarities with MPTP66. 
While paraquat cannot cross the BBB, its precise uptake mechanism is unknown. 
Studies indicate that paraquat may enter the brain through a carrier-mediated 
mechanism like a neutral amino acid transporter similar to LAT-167, followed by a DAT-
independent, Na+-dependent uptake mechanism to facilitate entry into DAergic 
neurons61, 68. Once inside neurons, paraquat induces rampant oxidative stress by 
producing superoxide free radicals from undergoing redox cycling69, as well as 
promoting a pro-apoptotic cascade involving Bak and Bax, cytochrome c release and 
caspase-9 activation70. Similar to rotenone, paraquat exposure in rodents does result in 
α-Syn aggregation in the SNpc, as well as loss of nigrostriatal DAergic neurons and 
motor impairments66, 71.  
LPS: Neuroinflammation has recently come to light as a component of PD pathogenesis. 
Accordingly, local administration of the bacterial endotoxin lipopolysaccharide (LPS) into 
the nigrostriatal tract results in DAergic neurodegeneration72. This model relies on LPS-
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induced activation of glia that subsequently release soluble factors, such as cytokines, 
RONS, and lipid metabolites that induce nigral cell death and motor deficits in animals73.  
Genetic Animal Models 
Although the majority of PD cases are sporadic in nature, about 10-20% of PD 
has documented genetic causes. Many PD-associated genes have been identified, 
including dj-1, pink1, parkin, nurr1, lrrk2, uch-l1, and SNCA2. In light of the work 
presented in this thesis, the current chapter will specifically focus on the three 
autosomal recessive genes responsible for early-onset PD, parkin, pink1 and dj1, and 
the autosomal dominant gene for α-Syn, SNCA.  
Parkin: PARK2/parkin encodes for a protein that consists of 465 amino acids, and 
contains a ubiquitin-like domain that is responsible for substrate recognition, along with 
RING finger domains that interact with other components of the UPS74. Parkin 
expression in the brain is distributed within basal ganglia structures, including the SN 
and caudate-putamen, but with some expression in the cerebellum as well75. Beside 
itself, Parkin has many substrates, including the synaptic vesicle-associated protein 
CDCrel-149, α-Syn50, synphilin-151, and the membrane receptor Pael-R76. Parkin has 
also recently been shown to form an E3 ligase multi-protein complex with DJ-1 and 
PINK1, two other proteins implicated in PD77. Homozygous mutations found in parkin 
have been linked to an early-onset familial form of PD, with no presence of Lewy 
bodies74. Parkin mutants show altered intracellular localization, along with altered 
substrate binding and enzymatic activity. Consequently, a functional effect of mutations 
in this gene is an inability to degrade substrate proteins78. Parkin -/- mice show an 
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increase in extracellular striatal DA concentration79, while wildtype parkin seems to 
increase cell surface expression of DAT for increased DA reuptake80. Parkin -/- mice 
also show impairments in synaptic plasticity81, as parkin seems to negatively regulate 
the strength and number of excitatory synapses82. However, while parkin knockout mice 
do not show overt loss of DAergic neurons79, mice expressing a truncated version of 
Parkin show both DAergic degeneration as well as hypokinetic deficits83.  
PINK1: Similar to parkin, homozygous mutations in PARK6/pink1 also result in an early-
onset form of PD84. Its protein product, PINK1 (PTEN-induced kinase 1) is a 
mitochondrial serine/threonine kinase with an N-terminal mitochondrial targeting 
sequence. PINK1 distribution appears to be uniform through the cortex, striatum, 
thalamus, brainstem and cerebellum85. Familial mutations result in defective kinase 
activity86 that is normally necessary for mitochondrial integrity, as its phosphorylation 
targets include mitochondrial fission and fusion factors87, as well as the mitochondrial 
serine protease HtrA288. Early effects of PINK1 loss in rats include decreased Complex I 
levels and increased ETC proton leak prior to the development of PD 
symptomatology89. Moreover, wildtype PINK1 has been shown to protect against 
mitochondrial toxin-induced DAergic cell death, as well as reducing apoptotic caspase 
levels and cytochrome c release from mitochondria90. Despite not showing loss of 
DAergic neurons, pink1 knockout mice show impaired DA release and age-dependent 
motor deficits that were accompanied by reduced striatal DA levels91, 92. As both parkin 
and pink1 knockout models have not confidently shown selective DAergic 
neurodegeneration on their own, a fish model and mouse embryonic fibroblasts lacking 
both parkin and pink1 shows both DAergic cell loss, locomotor dysfunction, and overt 
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mitochondrial deficits93. Such evidence brings to light the interconnected pathways 
between PINK1 and Parkin in PD, with Parkin able to rescue PINK1 loss94. Parkin is a 
PINK1 phosphorylation target, as PINK1’s kinase activity necessary to recruit Parkin to 
mitochondria with a lowered membrane potential35, 95, 96. Various modulators of this 
interaction have recently been introduced, including the Mtfn2 and voltage-dependent 
anion channels (VDACs)36, 97. The teamwork between Parkin and PINK1 reveals the 
importance of maintaining proper mitochondrial trafficking and turnover, signifying an 
impaired clearance of defective mitochondria as a potential mechanism behind PD 
pathophysiology.  
DJ-1: Moreover, mutations in PARK7/dj-1 are also responsible for an autosomal 
recessive, early-onset form of PD98. Originally identified as an oncogene, this gene 
encodes for DJ-1, a redox-sensitive chaperone protein that translocates from the 
cytoplasm to mitochondria following oxidation of a cysteine residue99. DJ-1 shows both 
peroxiredoxin-like peroxidase and glyoxylase activity100, 101. Mutations in dj-1 result in 
increased RONS levels and impaired mitochondrial energetics102, while overexpression 
of WT DJ-1 protects against DA toxicity and cell loss103. However, similar to parkin and 
pink1 knockout mice, DJ-1-/- mice do not show overt DAergic neurodegeneration in the 
SN, but do show alterations in DA reuptake and mitochondrial dysfunction104, 105. DJ-1 
may also protect cells through stabilization of the antioxidant transcription factor Nrf2 by 
blocking its interaction with its inhibitor protein Keap1106. Interestingly, DJ-1 has also 
been shown to form a multi-protein complex with parkin and pink177, though this 
remains controversial. Moreover, DJ-1 up-regulation can rescue the loss of PINK1-
mediated sensitization of DAergic neurons in the SNpc to a mitochondrial toxin94. The 
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rescue of pink1 loss-mediated mitochondrial deficits by DJ-1 was also seen in 
Drosophila, but showed no rescue in parkin mutants107.  These data reveal a role of DJ-
1 acting in parallel with the parkin/pink1 pathway.  
α-Syn: As previously mentioned, α-Syn plays a curious role in PD. SNCA encodes for 
this protein108. As the physiological role of α-Syn remains unclear, it is still under debate 
whether the protein is neuroprotective or neurotoxic. This disparity may be related to the 
overall expression level of the WT form. Low or wildtype expression of the protein may 
be protective against oxidative insults109, while high intracellular levels can promote 
abnormal and pathogenic aggregation of the protein110. Toxicity could also arise from its 
genetic state, as PD-associated mutations (A53T, A30P and E46K) can result in 
increased aggregation of the protein111, 112. A53T transgenic mice show aggregation of 
α-Syn that led to progressive neurodegeneration and significant motor deficits in 
contrast to mice expressing WT α-Syn113. Recent evidence has also suggested that the 
distinctive pathogenic mutations may result in unique fibril conformations, with A53T 
and E46K mutations exhibiting differences in secondary structures111. A53T transgenic 
mice also exhibit mitochondrial DNA damage and degeneration in neocortical, 
brainstem and motor neurons114. However, the severity of PD-associated phenotypes in 
their regional selectivity in α-Syn-mice may also be dependent on specific promoter-
driven expression. Mice overexpressing a pan-neuronal promoter-driven α-Syn for 
broad neuronal expression show preferential mitochondrial dysfunction in nigrostriatal 
DAergic neurons significantly earlier before loss of striatal dopamine115. Moreover, 
similar to the early-onset genetic models discussed above, transgenic α-Syn models 
have also struggled to recapitulate full DAergic neurodegeneration, despite showing 
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subtle changes in the nigrostriatal circuitry and/or damage to motor neurons and other 
neuronal circuits116. As with the potential interplay between the aforementioned 
autosomal recessive genes, interactions also exist with α-Syn itself. In addition to the 
aforementioned putative role of Parkin-mediated α-Syn regulation, DJ-1 has recently 
been found to protect against α-Syn (A30P)-mediated toxicity in DAergic neurons117, 
with wildtype DJ-1 able to reduce α-Syn dimerization118. As can be expected, the loss of 
both pink1 and overexpression of the A53T α-Syn mutation in mice results in increased 
neurotoxicity compared to either the loss of pink1 or the expression of A53T alone119. 
Similarly, pink1 overexpression has also shown rescue of α-Syn-induced locomotion 
and aging effects in Drosophila120. 
 
 Manganese 
Portions of this section have been published in the book chapter “Manganese” in 
Binding, Transport and Storage of Metal Ions in Biological Systems written by 
Chakraborty, Martinez-Finley, Caito, Chen and Aschner, as well as a review article in 
Toxicology Research written by Chen, Chakraborty, Peres, Bowman and Aschner. 
Routes of Exposure 
Manganese (Mn) is an essential heavy metal that comprises nearly 0.1% of the 
earth’s crust. It is the 5th most abundant metal and 12th most abundant element overall, 
usually existing in its natural form in the environment as oxides, carbonates and 
silicates. As erosion produces a naturally ubiquitous presence of Mn in air, soil and 
waterways, the human population is readily exposed to Mn through a variety of 
environmental sources. However, the primary route of Mn exposure is through dietary 
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intake, as several Mn-containing foods are found in human diets. Legumes, rice, nuts 
and whole grains contain the highest Mn levels, while Mn is also found in leafy green 
vegetables, tea, chocolate, and fruits like blueberries and acai121. Mn-containing 
nutritional supplements and vitamins are commonly taken on a daily basis, in addition to 
infant formulas that contain a trace element-enriched solution. The abundant Mn-
containing dietary sources allow humans to obtain the proper Mn levels (2.3 mg/day for 
men and 1.8 mg/day for women) necessary for several important physiological 
processes, including development, digestion, reproduction, immune function, energy 
metabolism and antioxidant defenses.  
Outside of dietary sources, exposure to inorganic forms of Mn can occur in 
several industrial settings, as Mn is used in the manufacturing of steel, batteries, 
fireworks, as well as ceramics, cosmetics, leather, glass and textiles. On the other hand, 
organic Mn is also highly prevalent in the environment, as Mn is a major component of 
the antiknock gasoline additive methylcyclopentadienyl Mn tricarbonyl (MMT), as well as 
fungicides and pesticides (e.g. Maneb and Mancozeb), smoke inhibitors, and as a 
medical magnetic resonance imaging (MRI) contrast reagent121.  
Intestinal Uptake and Release 
Ingestion is the most common route for Mn exposure. The typical adult ingests 
<5 mg Mn/kg, coming mostly from grains, rice, nuts, tea, and chocolate. Around 3-5% of 
ingested Mn is absorbed in adult humans, with radiolabeled 54Mn uptake studies 
showing that for a meal containing 1 mg Mn, adult males absorb 1.35 ± 0.51% while 
adult females absorb 3.55 ± 2.11%122, 123. Mammalian tissues typically contain 0.3-2.9 
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mg Mn/g wet tissue weight124. Turnover of ingested Mn is quick, with the mean retention 
of Mn 10 days after ingestion estimated at 5.0 ± 3.1% in women125. Mn levels are tightly 
controlled by absorption by the gastrointestinal (GI) tract and excretion by the liver. The 
majority of excreted Mn is in conjugation with bile in the liver and secreted into the 
intestines for elimination in the feces122, 126. There is a small amount of Mn that is 
reabsorbed in the intestines from the bile, forming an enterohepatic circulation127. Small 
amounts of Mn can also be excreted by the pancreas or via urine122.  
 Molecular mechanisms of Mn uptake by intestinal cells are not well characterized. 
Early studies using rat brush border membrane vesicles found evidence of a lactoferrin 
receptor-mediated uptake of Mn128. Studies using the Caco-2 intestinal cell line derived 
from human colonic carcinoma revealed a biphasic uptake process, indicating that 
transport falls into its steady-state condition following a brief period of equilibration 
between intraceullar and extracellular components129. Moreover, in vivo studies using 
rat intestinal perfusions have found that intestinal Mn uptake involves a high affinity, low 
capacity active transport process that is rapidly saturable130. It is thought that Mn can 
enter cells either through passive diffusion or active transport via the divalent metal 
transporter 1 (DMT1)131, 132. DMT1 is a transporter that uses the cell membrane’s proton 
gradient to move several divalent metals across the cell membrane, including Mn, Fe, 
and Cu132, and will be discussed in more detail later in this chapter. Due to this shared 
transport mechanism, trace metals have been shown to influence the amount of Mn 
absorbed. Other dietary components that alter Mn absorption include phytates and 
ascorbic acid133.  
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Absorption of Mn by the GI tract is modulated by a variety of factors. The 
concentration of Mn in the diet influences both the absorption of Mn and its elimination 
in bile. When instances of high Mn intake occur, either through the diet or environmental 
exposure, the GI tract absorbs less Mn, the liver increases metabolism, and there is 
increased biliary and pancreatic excretion122, 134, 135. Gender influences Mn uptake, with 
males absorbing significantly lower amounts of Mn than females122, 123. This may reflect 
men’s higher iron status and higher serum ferritin concentrations, which may compete 
with Mn for transport by DMT1. Age is another determinant of Mn absorption. Younger 
individuals, particularly infants, absorb and retain higher levels of Mn than adults136, 137, 
likely because their necessity for Mn is much higher than adults. Data concerning the 
intestinal absorption of Mn in infants compared to adults are limited, but studies have 
examined the detrimental effects of total parenteral nutrition (TPN) in severely ill or 
premature infants. These solutions are usually supplemented with a trace element 
solution that contains small amounts of Mn. However, unlike the minimal absorption of 
Mn from milk, the intravenous exposure to Mn-supplemented TPN solutions results in 
bypass of any intestinal control of absorption. Consequently, nearly 100% of Mn can be 
absorbed, resulting in conditions of toxicity in these vulnerable neonates. These infants 
also pass little stool, leading to even higher retention of Mn138.  
Transport Across the Cell Membrane 
To date, Mn is a unique heavy metal in that it does not have its own group of 
cellular transport proteins. Rather, it “piggybacks” on transport systems known to 
regulate other heavy metals.	  Mn3+ is mostly found complexed with the transferrin protein 
(Tf), which is then imported by the transferrin receptor (TfR). Following endocytosis of 
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this complex, Mn is released via endosomal acidification through a vacuolar ATPase (v-
ATPase)139, at which point Mn3+ is converted to Mn2+.	   However, divalent Mn is more 
prelavent than trivalent Mn and can be transported via the divalent metal transporter 1 
(DMT1)140. DMT1-mediated Mn import, the primary mode of Mn uptake, is also 
dependent on the proton gradient generated by a v-ATPase141. DMT1 can be found on 
endosomal membranes to transport converted Mn2+ into the cytoplasm, as well on the 
plasma membrane (Fig 2). DMT1 expression has been shown to co-localize with TfR142, 
indicating overlap between the two systems.  
DMT1, originally known as DCT1 (Divalent Cation Transporter 1) or NRAMP2 
(Natural Resistance Associated Macrophage Protein 2), transports a variety of divalent 
metals, including Mn2+, Fe2+, Cu2+, Zn2+, Co2+ and Cd2+. It was originally associated with 
iron transport, as a missense mutation in anemic Belgrade rats or microcytic mice was 
found to impair Fe uptake143, 144; however, its affinity to Mn is similar to that of Fe145. It 
has 12 transmembrane domains, and metal transport is coupled to the co-transport of a 
proton. While having ubiquitous tissue expression, DMT1 shows highest localilzation in 
the intestine, kidneys and brain. Light and electron microscopy has also found DMT1 
expression in glial cell bodies of the neocortex, subcortical white matter, and the 
hippocampus146, while immunocytochemistry has found dense DMT1 staining in the 
caudate, putamen, and SNpr of the monkey basal ganglia147. Rat pups exposed to Mn 
have increased levels of Mn in vivo, as well as increased DMT1 protein expression 
throughout the brain148.  Similarly, increased Mn uptake is seen upon impaired cellular 
iron status in astrocytic cultures, corresponding with enhanced DMT1 protein 
expression in these cultures149.  
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Figure 2. The mammalian Mn transport system. Various proteins involved in Mn 
transport into, within and out of the cell, including transport across the plasma 
membrane, as well as into the Golgi lumen and mitochondrial matrix.  
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While DMT1 is the primary mode of Mn uptake, other transporters also facilitate 
Mn uptake. For example, Mn can enter cells through the Zn transporters ZIP8 and 
ZIP14 that show high affinity for Mn2+ among other metals150, 151. These proteins are 
Mn2+/HCO3- symporters that facilitate Mn uptake into the brain, liver and kidneys. 
Another example is the choline transporter; in situ rat brain perfusion techniques show 
inhibition of brain choline uptake by Mn2+ and/or Cd2+, but not Cu2+ or Al3+ ions152. Mn 
can also be taken up through voltage-gated and store-operated calcium channels, and 
ionotropic glutamate receptor Ca2+ channels. These studies used electron paramagnetic 
resonance (EPR), calcium-selective dyes (Fura2) and calcium competition/inhibition 
studies to show the permeability of Ca2+ channels by Mn2+ ions153-155. Studies have also 
found a citrate transporter that can facilitate entry of Mn156, and Mn-bound citrate may 
be a substrate for the organic anion transporter, the monocarboxylate transporter (MCT), 
or members of the organic anion transporter polypeptide or ATP-binding cassette 
families157. Despite the breadth of knowledge concerning non-DMT1 transport 
mechanisms, it is relatively unknown how much these secondary mechanisms 
contribute to overall Mn uptake (Fig 2).   
Buffering and Other Regulatory Mechanisms 
Upon entering the cytoplasm, further mechanisms exist to help buffer intracellular 
Mn concentrations. Mn shows preferential accumulation in the mitochondria and is 
taken up by the mitochondrial calcium uniporter158, 159. This uniporter contains an 
external activation site that can bind Ca2+ to enhance uptake of both Ca2+ and Mn2+ 
through a specific transport site. Meanwhile, Mn efflux out of the mitochondria occurs 
through a very slow process that is Na2+-independent159. Moreover, the Golgi complex 
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also helps to sequester intracellular Mn through the secretory pathway Ca2+/ Mn2+-
ATPases (SPCAs). These pumps can bring in Mn2+ into the Golgi lumen (Fig 2), and 
show high expression in the brain160. Mutations in the SPCA1 gene (atp2c1) result in 
Hailey-Hailey Disease, an adult-onset skin condition that is characterized by frequent 
blistering and erosions161. High Mn2+ concentrations can inhibit ATPase activity of the 
pump, resulting in breakdown of Golgi organization in neurons that can be partially 
reversed by Mn chelation via EDTA (ethylenediaminetetraacetic acid)162. This indicates 
that SPCAs are effectively able to pump Mn2+ into the Golgi complex at lower 
concentrations, whereas higher concentrations result in inhibition and breakdown.  
Additional homeostatic processes can include binding to Mn-dependent 
metalloenzymes or proteins. As Mn is a vital cofactor for many enzymes, proper 
metalloregulation is key in promoting optimal intracellular Mn levels, with some of this 
regulation occurring in a cell type-specific manner. Within the brain, astroglia are 
thought to be a significant sink for Mn accumulation. This is primarily due to the 
localization of glutamine synthetase (GS) within astroglia, an enzyme necessary for the 
glutamate-glutamine shuffle. Nearly 80% of brain Mn is found associated with GS, as 
Mn is a necessary cofactor for GS activity163. Consequently, the abundance and 
selectivity of Mn accumulation in these cells can result in astroglia being the initial 
targets of toxicity. Similar to GS, there are several other enzymes that require Mn for 
proper enzymatic function. These include Mn-SOD or SOD2, the aforementioned 
antioxidant mitochondrial protein that converts superoxide into hydrogen peroxide and 
O2. Another Mn-containing mitochondrial protein is pyruvate carboxylase (PC), which 
catalyzes the carboxylation of pyruvate to oxaloacetate and serves as a bridge between 
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carbohydrate and lipid metabolism164. PC can depend on a magnesium ion instead of 
one Mn ion as a cofactor for proper functioning165. Yet another Mn-containing 
metalloenzyme is arginase (ARG1 and ARG2). This enzyme plays a vital role in the 
urea cycle, and requires two Mn ions in order to convert arginine into urea and 
ornithine166. Finally, certain serine/threonine protein phosphatases (PPMs) are also 
metal-dependent (PP2C), requiring two Mg2+ or Mn2+ ions for their function in 
dephosphorylating proteins at their serine and threonine sites, a very important post-
translational protein modification167.  
Genetic regulation of Mn transporter expression also plays a role in proper Mn 
homeostasis. Mammalian systems show evidence of the important role of transcriptional 
regulation of Mn transporters, such as that of DMT1168. DMT1 has four mRNA isoforms 
encoding four different proteins that differ either in their N- and C-terminals or 5’ vs. 3’ 
processing. Two of the alternatively spliced isoforms differ in their transcription start 
sites: Exon 1A contains an AUG codon that extends its N-terminal, while Exon 1B lacks 
this initiator codon and, consequently, has translation begin in exon 2. Meanwhile, two 
of the isoforms contain an iron responsive element (IRE) in the 3’ UTR of the DMT1 
mRNA. IREs serve as a very important sensing mechanism. If iron levels are low (which 
can indirectly affect intracellular Mn concentrations), iron regulatory proteins (IRPs) are 
thought to bind the IRE in the IRE-containing DMT1 isoforms to stabilize the IRE-
containing message169. The presence of such isoforms and the influence of iron on their 
expression most likely has an effect on intracellular Mn concentrations as well, though 
further studies must be conducted to look at their direct relationship. Interestingly, 
Parkin has been shown to promote degradation of an isoform of DMT1 in vitro through 
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the proteasome170. 
Manganese Efflux 
Until recently, the only known Mn efflux mechanism in vertebrates at the cell 
membrane was through the iron exporter ferroportin (FPN) (Fig 2). This protein consists 
of 12 transmembrane domains, with mutations resulting in the iron overload diseases 
“ferroportin disease” or type 4 haemochromatosis171. FPN is regulated by the hormone 
hepcidin, which promotes its internalization and degradation to help regulate optimal Fe 
levels; FPN mutations can also cause inefficient binding to hepcidin to impair this 
process172. In terms of Mn transport, Yin et al. have demonstrated that Fpn expression 
decreases Mn accumulation in cells to help ameliorate Mn-induced cytotoxicity by 
rescuing cell membrane leakage and Mn-induced reductions in glutamate uptake. 
Moreover, mice exposed to Mn exhibit increased FPN protein levels in the cortex173. 
These findings were further supported by export of Mn in Xenopus laevis oocytes 
expressing human FPN (SLC40A1)174, where Mn accumulation was decreased in a 
concentration-dependent manner and could be inhibited by lower pH levels. Moreover, 
FPN-mediated Mn efflux can also be partially inhibited by addition of Fe, Co or Ni174. 
However, it is currently unclear whether FPN is able to export the same range of 
divalent metals that a transporter like DMT1 can import. Mitchell et al. showed evidence 
in oocytes of Co and Zn efflux through FPN, but also disagreed with previous studies in 
FPN’s ability to efflux Mn175. Though additional studies must be conducted to further 
FPN’s role in Mn toxicity, it is logical that Mn would share the same exporter as Fe in 
the same way they share uptake routes.  
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Interestingly, recent findings from Tuschl et al. have described the zinc 
transporter, SLC30A10, as another putative Mn exporter. This study utilized whole-
genome homozygosity mapping and sequencing to find alterations in the SLC30A10 
gene sequence in families with hypermanganesemia and Parkinsonism. Human 
wildtype (WT) SLC30A10, and/or SLC30A10 missense or nonsense mutations were 
inserted into the Mn-sensitive yeast strain Δpmr1. It was found that Δpmr1-expressing 
wildtype SLC30A10 rescued growth, while Δpmr1 expressing SLC30A10 mutations 
retained Mn sensitivity, suggesting that WT SLC30A10 is important for Mn efflux176. 
Moreover, a comprehensive study by Leyva-Illades et al. recently established 
SLC30A10 as a plasma membrane-localized Mn exporter (Fig 2) in both the 
invertebrate Caenorhabditis elegans model and primary midbrain neurons cultured from 
WT mice. Mutations in this gene associated with familial Parkinsonism resulted in 
impaired trafficking of the transporter to the cell surface, diminished Mn efflux and 
increased sensitivity to Mn exposure177. The role of impaired metal homeostasis in 
Parkinsonism is further supported by the ability of metal chelation in patients with 
mutated SLC30A10 to improve clinical symptoms, decreased blood Mn levels and 
improved MRI hyperintensities in the basal ganglia178, 179. While chelation may take a 
longer duration to reverse Parkinsonism in patients carrying SLC30A10 mutations, 
these studies still highlight the importance of treatable Parkinsonism that is associated 
with metal transporter mutations. 
Manganese Toxicity 
 The wide variety of proteins involved in regulating Mn reflects the need to 
balance homeostasis between necessity and toxicity, as excess Mn can result in a 
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neurotoxic condition known as “manganism.” James Couper first identified this condition 
in 1837 in five industrial workers exposed to high levels of manganese from the use of 
manganese oxide in the production of chloride for bleaching power. Mn poisoning leads 
to irreversible damage to the basal ganglia brain region that is also affected in PD, 
resulting in similar cognitive, emotional and motor deficits157, 180. This condition mostly 
arises from occupational exposure to Mn, including miners, welders, smelters and other 
industrial workers who handle Mn-containing steel and other manufacturing, and 
subsequently inhale fumes containing high levels of Mn181, 182.  
In addition to industrial workers exposed to high Mn levels at their workplace, 
there are other populations at risk of Mn-induced toxicity. Patients suffering from hepatic 
encephalopathy or any stage of liver failure are at high risk of Mn toxicity, as a properly 
functioning biliary system is required for proper Mn excretion183. Similarly, unhealthy 
neonates partaking in Mn-supplemented TPN are also vulnerable to Mn toxicity184. 
Another significant population at risk for Mn poisoning are those suffering from Fe 
deficiency, one of the most common nutritional deficiencies in the world. This is due to 
the fact that Fe and Mn compete for the same transporters, resulting in higher Mn 
accumulation when Fe levels are low185, 186. Thus, in people suffering from chronic iron 
deficiency (e.g. iron deficiency anemia), low levels of Fe can result in high Mn 
accumulation over time.  
Manganism & PD 
Despite their overlap, manganism is still a differential diagnosis from PD, with 
distinctive areas of initial cell death that produce some contrasting symptomatology. 
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Though bradykinesia and rigidity are still noticeable, tremor is not as evident in 
Manganism patients187. Moreover, unlike PD, dystonia is more highly prevalent in 
manganism; patients also exhibit a tendency to fall backwards.188 Similar to PD, 
however, manganism is progressive in nature, with only partial recovery of certain 
symptoms following elimination of the source of overexposure for an extended period of 
time189. 
While PD initially targets the DAergic cells of the SNpc, Mn preferentially 
accumulates in and damages the GABAergic cells of the globus pallidus and corpus 
striatum before spreading to other brain regions187, 190, 191. Consequently, the major 
difference lies in the fact that one condition destroys cells responsible for dopamine 
production, while the other targets the receptor cells that react to dopamine. 
Distinguishing between the two conditions relies heavily on a variety of biomarkers and 
tests specific for each condition. Diagnostics using magnetic resonance imaging (MRI) 
techniques can visualize the increased signal intensities in the globus pallidus in T1-
weighted images, though they will disappear within six months to a year of removing the 
source of Mn exposure. Moreover, a positron emission tomography (PET) scan can also 
distinguish between manganism and PD: manganism patients show a normal scan, 
while PD patients show reduced striatal uptake of the radioactively labeled analog of the 
dopamine precursor DOPA (18-fluorodopa)187, 192. Another potential biomarker for 
manganism was recently identified using voxel-based morphometry (VBM). The study 
found that compared to healthy control subjects, welders chronically exposed to Mn 
possess decreased brain volumes in the globus pallidus and cerebellum that correlate 
with cognitive and motor deficits193. Another key difference between manganism and PD 
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is the lack of effectiveness of L-DOPA treatment for manganism, contrary to PD194. 
Instead, treatment with the metal chelators EDTA and sodium para-aminosalicylic acid 
(PAS) has shown to be beneficial in some cases195, 196, though this option may be most 
beneficial before the condition has progressed too far.  
The association between occupational exposure to Mn-containing fumes (e.g., 
those experienced by welders) and Parkinsonism remains controversial in the literature. 
A cross-sectional study conducted in 2006 found a higher prevalence of Parkinsonism 
in Alabama welders compared to age-matched control subjects197. The same group 
recently published another study showing that Mn-exposed welding workers had similar 
scores (>15) on a commonly used questionnaire for PD motor evaluation (UPDRS3, or 
Unified Parkinson's Disease Rating Scale motor subsection 3) compared to newly 
diagnosed, untreated idiopathic PD (IPD) patients181. Yet, other studies have not found 
an increased risk for PD in welders. A 2012 Danish study198 and a 2005 study using 
data from movement disorder clinics199 found no positive association between PD and 
welding. However, the former study relied on hospital contacts, and the latter study 
relied on specialty clinic surveys to define Parkinsonism, compared to clinical 
examinations and/or the UPDRS3. The discrepancies in these studies may be due to 
differences in defining PD in their cohorts, as well as varying welding exposures to Mn.  
 The association between non-occupational Mn exposure and Parkinsonism is 
also unclear. A 2009 study from a mining district in Mexico found attention impairments 
in a population where a majority of participants were exposed to Mn in ambient air at 
levels higher than the recommended Environmental Protection Agency’s (EPA) 
guidelines for non-occupational environments (>0.05 µg/m3)200. Similarly, a study on the 
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general population living near a ferromanganese refinery in Ohio found slight, 
subclinical impairments in postural balance upon chronic exposures to Mn in ambient 
air201. Moreover, a recent 2013 study on a population living close to a manganese 
processing plant found decreased olfactory function compared to a population living far 
from the plant202. Yet, other studies have found minimal effects of Mn on the general 
population. A study on the role of MMT from gasoline combustion compared garage 
mechanics vs. blue-collar workers and found no significant difference between the two 
groups in whole blood Mn concentrations, with no obvious health problems203. Likewise, 
a more recent study found limited evidence for any association between ambient metal 
exposure in adults and the risk of PD using a nurses’ cohort and the EPA Air Toxics 
data204. More studies must be done to investigate the long-term effects of chronic, low-
dose Mn exposure to the general human population, be it from gasoline combustion or 
other non-occupational sources found in ambient air.  
Shared Molecular Mechanisms 
  Though the literature remains disputed in the connection between environmental 
Mn exposure and Parkinsonism, the molecular mechanisms behind both PD and 
manganism share several key processes. A major hallmark of both conditions is 
increased oxidative stress. Similar to dopamine oxidation in PD, high Mn levels can 
result in increased oxidative stress through a variety of mechanisms. Mn can directly 
inhibit complexes of the electron transport chain in the mitochondria that are responsible 
for ATP production. This inhibition results in both the leakage of damaging free radicals, 
as well as ATP depletion in the cell205. Recent in vitro evidence using the human 
neuroblastoma SH-SY5Y cell line has found Mn-induced changes at the DNA level, with 
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increased accumulation of DNA single strand breaks and oxidized thymine bases. 
However, pre-treatment with antioxidants could rescue these signs of oxidative damage, 
further supporting the role of Mn in increasing oxidative stress in human cells206. Mn can 
also result in apoptotic cell death through the activation of multiple caspases207-209. 
Moreover, Mn-exposed Gli3 cells (a human astrocyte line) show a loss in mitochondrial 
membrane potential and caspase-9 activation, with concomitant alterations in 
mitochondrial fission and fusion protein levels resulting in enhanced fragmentation210. 
Manganese has also been shown to affect glutamate transporter levels and overall 
glutamate neurotransmission, resulting in cell death from glutamate excitotoxicity, a 
phenomenon also seen in PD211. Another hallmark of both conditions is increased 
protein aggregation, with dopamine oxidation as a potential modifier of protein 
aggregation states in PD212. Similarly, Mn can induce aggregation of α-Syn213. The 
crosstalk is further evident by the fact that Mn itself can enhance DA oxidation214 and 
cause internalization of DAT215; Mn accumulation following high doses requires 
functional DAT specifically in the striatum216. 
The interaction between Mn toxicity and PD-associated proteins has recently 
become a focus of studies in humans. Increased expression of a DMT1 isoform has 
been found in the SN of PD patient brains, while DMT1 expression is also significantly 
increased in MPTP-treated mice that also exhibit enhanced Fe accumulation and 
DAergic cell death217. Furthermore, a specific polymorphism in DMT1 (the CC 
haplotype) has recently been associated with PD in a Chinese cohort218. In the first 
study of its kind, Aboud and colleagues differentiated fibroblasts into human induced 
pluripotent stem cell (hiPSC)-derived early neural progenitor cells (NPCs) from a patient 
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carrying a mutation in parkin and a control subject. Though no difference in Mn 
cytotoxicity or mitochondrial fragmentation was found between the subjects, increased 
Mn-dependent RONS generation was found in the NPCs carrying the parkin deletion219. 
Furthermore, the increased RONS occurred in the face of decreased Mn accumulation 
in the parkin mutant cells. The role of dopamine in this interaction has been examined in 
vitro. Roth and colleagues found that human lymphocytes (immune cells that lack 
dopamine) from patients expressing mutated parkin show increased mitochondrial 
dysfunction from Mn exposure compared to control lymphocytes. However, they do not 
exhibit any difference in Mn-induced cell death or Mn accumulation220. Additionally, 
Parkin is able to selectively protect against Mn toxicity in a DAergic cell-specific 
manner221. Finally, rats exposed to Mn-containing welding fumes show increased 
protein levels of Parkin, in addition to the loss of TH and increased oxidative stress222.  
 
Caenorhabditis elegans as a Neurotoxicity Model 
Portions of this section have been published in a review article in International Journal 
of Molecular Sciences written by Chakraborty, Bornhorst, Nguyen and Aschner223, as 
well as a review article in Journal of Trace Elements in Medicine and Biology written by 
Chakraborty and Aschner224. 
 
 
While the majority of animal studies in the PD literature utilize rodent models, the 
invertebrate Caenorhabditis elegans (C. elegans) model provides several appealing 
advantages to investigate the connection between Mn toxicity and PD genetics. While  
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Figure 3. C. elegans dopaminergic head neurons. Arrowheads denote 
the four DAergic neurons in the head of a nematode, with dendritic 
processes extending to the tip of the nose.  
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these nematodes do not possess a brain, they do contain all necessary components of 
the DAergic system225. This includes the homologs of the dopamine transporter (DAT-
1)226; the vesicular monoamine transporter 2 (CAT-1)227; tyrosine hydroxylase (CAT-
2)228 and dopamine receptors (DOP-1 through DOP-4)229. Out of the total 302 neurons, 
hermaphroditic worms possess eight DAergic neurons: four CEP (cephalic) (Fig 3) and 
two ADE (anterior deirid) neurons in the head, as well as two PDE (posterior deirid) 
neurons in the tail225. Male worms contain six additional DAergic neurons in the tail. 
Neurons can be visualized through their transparent bodies using a fluorescent reporter, 
like green fluorescent protein (GFP), that can be driven under the dat-1 promoter (e.g., 
pdat-1::GFP)230. Through the use of fluorescent and confocal microscopy, degeneration 
can be visualized by the presence of puncta and blebbing along dendritic processes; 
shrinking of soma; dendritic strand breaks; and loss of soma and dendrites.  
Moreover, dopamine-dependent behaviors, such as basal slowing response 
(BSR) can also be assayed in C. elegans. BSR is a feeding behavior that is assayed via 
alterations in the number of body bends in response to food availability. Using animals 
lacking cat-2, the rate limiting enzyme of dopamine synthesis, Sawin et al. showed that 
dopamine is required for animals to sense a bacterial lawn. Exogenous dopamine 
administration can reverse this phenotype and rescue responses to WT levels. The 
authors also concluded that this response is due to the mechanical sensation, rather 
than chemosensory features, of bacterial stimuli228. Thus, this assay can be utilized to 
investigate the effects of a toxicant and/or genetic mutations on the integrity of the 
dopaminergic system, as a comparison between the WT and cat-2 mutant response.  
	   34	  
Additionally, the C. elegans genome has been fully characterized231, allowing for 
ease in studying genetic models of PD. Especially with a short lifespan (two to three 
weeks) and a quick life cycle (three days), the ease in unbiased, forward genetic 
screens has made C. elegans an attractive model to study neurodegeneration in PD232. 
Nematodes are first mutagenized to induce DNA mutations, followed by the isolation of 
animals with distinctive phenotypes of interest. In terms of PD, these phenotypes 
typically involve altered DA neuronal morphology or a DA-specific behavior. Genetic 
mapping of progenies showing the modified trait is used to determine the location of the 
altered loci included3. Because C. elegans reproduce quickly to generate 200-300 
worms in one brood, genetic screens involving large numbers of animals can be 
performed within a relatively short amount of time. 
Alternatively, reverse genetics is also a simple approach to study the effects of a 
specific gene of interest that may be involved in neurodegeneration. Transgenesis in 
worms is typically accomplished through microinjection and bombardment techniques. 
The former involves microinjecting a plasmid containing the regulatory sequence of the 
gene of interest fused to a fluorescent reporter that can later be used as a readout for 
that gene. Similarly, subcellular targeting sequences (like the nuclear localization signal, 
NLS; or the mitochondrial targeting sequence, MTS), as well as cell or tissue-specific 
promoters (e.g., the aforementioned pdat-1::GFP transgene) can also be included in the 
plasmid to drive targeted gene expression. Microinjection usually results in an unstable, 
extrachromosomal array, requiring the subsequent use of ultraviolet (UV) or gamma 
irradiation to fully integrate the transgene233. A second technique involves microparticle 
bombardment, otherwise known as biolistic transformation. Although this results in low-
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copy expression, the desired transgene is fully integrated into the genome234. The 
commercial availability of genetic knockout animals through the Caenorhabditis 
Genetics Center (CGC) is possible due to distribution of isolated deletion mutants from 
both the National BioResource Project of Japan (NBRP) and the C. elegans Gene 
Knockout Consortium (GKC)235.  
PD Genetics Homology in C. elegans 
 In addition to showing conservation of the DAergic system, worms also contain 
homologs for several of the genes associated with autosomal recessive PD, including 
parkin, pink1 and dj1. There is no known homolog for the SNCA gene in the C. elegans 
genome. 
parkin/pdr-1 
 
 In C. elegans, pdr-1 (PD related 1) is a homolog for parkin that shows 
conservation of its protein function as an E3 ubiquitin ligase. Similar to parkin, the pdr-1 
homolog is ubiquitously expressed in the worm, and shows high expression in both cell 
bodies and dendrites of neurons236. This gene in worms demonstrates how vulnerability 
to particular toxicants may be specified by a particular genetic mutation. For example, 
compared to wildtype worms, pdr-1 knockout worms show increased lethality and 
shortened lifespan upon exposure to methylmercury (MeHg) that correspond to 
increased RONS induction. However, the pdr-1 mutants do not show the same 
dopamine-dependent behavioral deficits that wildtype worms do upon MeHg 
exposure237. On the other hand, these same pdr-1 knockout worms also exhibit 
increased lethality and shortened lifespan upon Mn exposure, yet they do show 
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enhanced Mn-induced DAergic neurodegeneration compared to wildtype worms. 
Interestingly, pdr-1 deletion mutants do not exhibit sensitivity to paraquat, FeCl2 or 
CuCl2 treatment, but do show sensitivity to rotenone treatment238.  
pink1/pink-1 
  While the pink1 homolog in worms, pink-1, has not been studied in depth, it 
shows conservation in cytoplasmic and mitochondrial localization, as well as its serine-
threonine kinase domain. Moreover, in response to paraquat-induced RONS generation, 
pink-1 deletion mutants exhibit shortened mitochondrial cristae and neuronal axon 
pathfinding defects239. More studies are necessary in examining whether its role in 
mitophagy, along with pdr-1’s contributions, is conserved in C. elegans.  
dj1/djr-1.1 and 1.2 
  Nematodes contain two homologs for DJ-1 (DJR-1.1 and DJR-1.2) that exhibit 
differential tissue expression patterns. DJR-1.1 in C. elegans is detected in both the 
nucleus and cytoplasm, while DJR-1.2 shows cytosolic expression in head neurons101. 
DJR-1 knockout worms exhibit increased vulnerability to rotenone-induced toxicity that 
can be rescued by a combinatory treatment of the mitochondrial complex II activator D-
ßhydroxybutyrate and the anti-apoptotic tauroursodeoxycholic acid238. DJ-1 also 
possesses glyoxalase activity that is vital in detoxifying reactive glyoxals to prevent the 
formation of advanced glycation end products that have been observed in PD. While 
DJR-1.1 is more efficient than DJR-1.2 in protecting worms against glyoxals, DJR-1.2’s 
neuronal expression confers protection against gloxyal-induced DAergic cell death101. 
Furthermore, dauer-stage worms show markedly increased expression of DJR-1.2 that 
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is mediated by DAF-16, the C. elegans homolog for the mammalian FoxO protein that 
regulates entry into this stage. Moreover, djr-1.2 expression is also likely to be regulated 
by insulin signaling240.  
Manganese Transporter Homology in C. elegans 
The C. elegans genome also contains homologs for key components of Mn 
transport. Similar to the PD-associated genes, worms homologs possess multiple 
isoforms for a particular gene that may contribute unique aspects of the total function.  
Uptake via DMT1/SMF1-3 
 Au et al. characterized an intricate Mn transport mechanism in C. elegans 
by investigating the homologs for DMT1: SMF1, SMF2 and SMF3.  Protein sequence 
analysis was conducted to find that all three homologs show high homology to human 
DMT1 and contain both the characteristic 12 transmembrane domains and a consensus 
transport sequence (CTS). Deletion mutants of the three homologs from the CGC were 
then used to assess whether loss-of-function or down-regulation of these transporters 
confers sensitivity to Mn exposure. Both smf-1(eh5) and smf-3(ok1035) deletion 
mutants exhibited heightened resistance to an acute (30 minutes) MnCl2 exposure 
when compared to wild-type Bristol N2 worms. This was evident with a significantly 
higher LD50 for these mutants 24 hours after treatment. smf-1(eh5) mutants were almost 
twice as resistant to Mn as wild-type worms, with an LD50 of 94 mM MnCl2 compared to 
the N2 LD50 of 47 mM. smf-3(ok1035) deletion mutants showed an even higher level of 
resistance, with an LD50 of 126 mM241. These data suggest that these two homologs 
somehow mediate Mn uptake, as the lack of functional SMF1 and SMF3 does not 
increase sensitivity to Mn compared to wildtype worms. On the other hand, smf-
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2(gk133) deletion mutants exhibited hypersensitivity to Mn exposure compared to wild-
type worms (LD50  of 26 mM), suggesting that functional SMF2 is somehow protective 
against Mn toxicity in worms.  
To further corroborate the role of the SMF proteins in regulating Mn homeostasis, 
metal content analysis was conducted using graphite furnace atomic absorption 
spectrometry (GFAAS). All strains showed increases in Mn accumulation in a dose-
dependent manner. smf-1(eh5) deletion mutants accumulated less Mn than wildtype 
worms, though not significant at any of the concentrations assessed. However, smf-
3(ok1035) mutants accumulated the least amount of Mn compared to all other strains, 
reaching significantly lower levels at 100 mM and 150 mM MnCl2. Interestingly, the smf-
2 deletion mutants exhibited significantly higher Mn content than the other strains upon 
exposure to 35 mM, 100 mM and 150 mM MnCl2241. These Mn content data paralleled 
the Mn toxicity evidence: without SMF1 and SMF3, the treated worms cannot 
accumulate Mn upon exposure, indicating a prominent role for uptake.  
  In order to investigate differential expression patterns, transgenic worms 
expressing GFP under the control of the smf1, smf2, or smf3 promoters were created, in 
addition to strains expressing GFP-tagged SMF1, SMF2 and SMF3. Using both 
transcriptional and translational fusion strains, both SMF1 and SMF3 show localization 
to major epithelial tissues (intestine, rectal gland cells, uterus, vulva, epidermis and 
sensory organs), whereas SMF2 remains in minor epithelial (pharynx, pharyngeal-
intestinal valve) 3. At the cellular level, SMF1 and SMF3 also both localize to the apical 
membrane, while SMF2 is mostly cytoplasmic. Upon Mn exposure, SMF1::GFP and 
SMF2::GFP reporter strains show no change in localization or expression. SMF3::GFP, 
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however, shows a remarkable change in both localization and GFP intensity upon acute 
exposure to Mn. One hour post-treatment, SMF3::GFP worms show a dramatic 
translocation of SMF3 into apical vesicular compartments in the intestine. However, five 
hours after treatment, this intestinal GFP signal significantly decreases and is no longer 
localized to apical vesicles. This process is completely reversible, as SMF3::GFP 
worms return their expression level and intracellular localization to normal by 30 hours 
post-treatment241. Thus, these studies indicate an interconnected network of Mn 
homeostatic control through three homologs: SMF1 and SMF3 are the DMT1 isoforms 
responsible for Mn uptake in C. elegans, with SMF3 being the most DMT1-like homolog.  
Efflux via FPN/FPN-1.1-1.3 
 Similar to mammalian systems, Mn efflux is less understood than Mn uptake in 
worms. The C. elegans genome contains three homologs for this Mn/Fe exporter: FPN-
1.1, FPN1.2 and FPN1.3.  While not much is yet understood about their separate 
functions, fpn-1.1 shows the highest homology to mammalian fpn and is expressed in 
the intestine and muscle. Its expression in mammalian cells results in iron export and 
plasma membrane localization, with iron deprivation resulting in internalization. 
However, while mammalian FPN has a hepcidin-binding domain, C. elegans lack 
hepcidin genes. Consequently, FPN-1.1 lacks the critical cysteine residue needed for 
this interaction and subsequent regulation242.  
Intracellular buffering via PMR1/CePMR-1  
 Intracellular Mn buffering in C. elegans has not yet been fully elucidated. 
However, the nematode genome does contain a homolog for the P-type ATPase pump 
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known to transport both Ca2+ and Mn2+into Golgi apparatus243. This homolog, CePMR-1, 
shows expression in hypodermal seam cells, intestine and spermatheca, with 
conservation of its subcellular localization in Golgi apparatus. pmr-1 knockdown results 
in increased sensitivity to MnCl2 exposure and enhanced resistance to paraquat. Further 
linking this pump to intracellular Mn regulation, pmr-1 knockdown also ameliorates 
paraquat-induced toxicity of smf-3 RNAi worms244. Interestingly, the loss of pmr-1 also 
results in resistance against α-Syn-mediated DAergic cell death in C. elegans245, 
providing additional support for the role of Mn toxicity in Parkinsonism.  
 Unlike mammalian evidence for Mn sequestration into mitochondria via the Ca2+ 
uniporter158, no studies have investigated a similar transport mechanism in C. elegans. 
However, our laboratory has found evidence of a putative MTS in the N-terminal of 
SMF-3241. While our published studies do not show mitochondrial localization in 
epithelial tissues, future studies should investigate the potential of SMF-3 mediated, 
mitochondrial Mn import in C. elegans neurons. 
 
Overview of Specific Aims 
 Though genetic causes have been linked to PD, there is evidence of 
heterogeneity in age-of-onset and symptomatology in these cases. Moreover, the 
majority of PD cases remain idiopathic in nature. Together, these findings suggest the 
possibility of contributions from environmental factors, like Mn, in PD pathogenesis. The 
convergence of Mn toxicity and Parkinsonism on the same brain region (basal ganglia) 
to produce similar phenotypic outcomes also warrants further investigation into the 
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“multiple-hit” hypothesis behind PD, which questions whether a particular genetic risk 
factor increases susceptibility of DAergic neurons to environmental risk factors. Using 
the invertebrate C. elegans model system, the work presented in this thesis aims to 
investigate putative gene-environment interactions between PD genetic risk factors and 
Mn toxicity. The overarching hypothesis of this thesis is that the presence of early-onset 
PD genetic risk factors will increase vulnerability to Mn toxicity in C. elegans, ultimately 
resulting in damage to the DAergic system. 
Chapter 2: The effects of pdr-1, pink-1, and djr-1 loss on Mn toxicity will be discussed. 
This chapter supports the protective nature of human wildtype α-Syn expression in C. 
elegans against Mn toxicity in the background of pdr-1 and djr-1 loss, and implicates a 
role of increased extracellular dopamine in preventing α-Syn–mediated rescue of 
DAergic neurodegeneration. 
Chapter 3: The role of pdr-1 in Mn homeostasis will be discussed. In particular, the loss 
of pdr-1 results in altered mRNA expression of fpn-1.1, with fpn-1.1 overexpression in 
pdr-1 mutants improving Mn-induced lethality, oxidant metal accumulation, 
mitochondrial DNA integrity and DA-dependent behavioral output.   
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CHAPTER II 
 
 
THE EFFECTS OF PDR-1, PINK-1 AND DJR-1.1 LOSS IN MANGANESE 
-INDUCED TOXICITY AND THE ROLE OF α-SYN IN C. ELEGANS246 
 
 
 
Introduction 
Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder in the U.S., affecting nearly 1% of the population 121. With an age of onset 
typically around 60 years of age, this disease manifests a selective dopaminergic 
(DAergic) neuronal loss in the substantia nigra pars compacta (SNpc), resulting in overt 
motor and cognitive deficits 1. The cardinal motor symptomatology of PD includes 
bradykinesia, rigidity, tremors and postural instability that may be preceded by 
emotional instability and cognitive problems 2. As age remains the most significant risk 
factor for PD pathogenesis, the ever-increasing human lifespan has produced a 
financial and emotional burden worldwide. Untenable treatment options that do not 
target the etiology of PD are a major public health concern, and warrant further 
investigations into the specific mechanisms behind PD pathophysiology. 
While the majority of PD cases are idiopathic, many genes have now been 
associated with the disease, including DJ1, PINK1, parkin, NURR1, LRRK2, UCH-L1, 
and α-synuclein 2. The current study focuses on the major early-onset, familial PD 
genes: parkin, pink1 and dj1. Homozygous mutations in the PARK2/parkin gene are 
responsible for nearly 50% of an autosomal recessive, early-onset, familial form of PD 74. 
This gene encodes for an E3 ubiquitin ligase involved in the ubiquitin proteasome 
system (UPS) that targets substrates for degradation 49. Mutations in this gene result in 
impaired ligase activity and substrate binding that can lead to increased protein 
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aggregation 78. Parkin knockout (KO) models show a variety of PD-associated 
phenotypes, including hypokinetic deficits, DAergic cell loss 247 and increased 
extracellular dopamine (DA) levels in the striatum 79.  
The PD-associated protein known as PINK1, or PTEN-induced kinase 1, is a 
mitochondrial-targeted protein that contains a highly conserved serine/threonine kinase 
domain 248, 249. Homozygous mutations in pink1 are also connected to autosomal 
recessive, early-onset PD 84. These mutations typically result in impaired kinase activity 
86 that is otherwise critical for maintaining mitochondrial integrity, as phosphorylation 
targets include mitochondrial fission and fusion factors 87, as well as the mitochondrially-
located serine protease HtrA2 88. Wildtype PINK1 has been shown to protect against 
mitochondrial toxin-induced DAergic cell death, as well as reducing apoptotic caspase 
levels and cytochrome c release from mitochondria 90. Pink1 mutants show increased 
DAergic cell death 250 and impaired DA release 91.  
Recent studies have identified parkin as a PINK1 phosphorylation target. In fact, 
these two proteins work in parallel to promote mitophagy through a PINK1-mediated 
phosphorylation (and autophosphorylation) and recruitment of parkin to mitochondria 
with a lowered membrane potential 35, 95, 96. Various modulators of this interaction have 
recently been introduced, including the mitochondrial fusion factor Mitofusin 2 (Mtfn2) 
and voltage-dependent anion channels (VDACs) 36, 97. This novel role for both parkin 
and PINK1 reveals the importance of maintaining proper mitochondrial trafficking and 
turnover, signifying an impaired clearance of defective mitochondria as a potential 
mechanism in the pathophysiology of PD. 
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Additionally, mutations in the PARK7/dj1 gene are also associated with 
autosomal recessive, early-onset PD 98. This gene encodes for a protein that functions 
as an oxidative stress sensor, where oxidation of a cysteine residue results in 
translocation of the acidic isoform from the cytoplasm to mitochondria 99. Mutations in 
dj1 result in increased RONS levels, impaired mitochondrial energetics 102 and DAergic 
cell death, while overexpression protects against DA toxicity and cell loss 103. 
Interestingly, DJ1 has also been shown to form a multi-protein complex with parkin and 
pink1 77, though this remains controversial. Moreover, DJ1 up-regulation can rescue the 
loss of PINK1-mediated sensitization of DAergic neurons in the SNpc to a mitochondrial 
toxin 94. The rescue of pink1 loss-mediated mitochondrial deficits by DJ1 was also seen 
in Drosophila, but showed no rescue in parkin mutants 107. These data reveal a role of 
DJ1 acting in parallel with the parkin/PINK1 pathway.  
Another gene implicated in PD pathophysiology is SNCA 108 that encodes for α-
synuclein (α-Syn), the major aggregated component of Lewy body depositions. 
Pathogenic mutations in the SNCA gene have been shown to promote increased 
aggregation of the protein 111, 112. While the function of α-Syn remains unclear, high 
expression is found in neuronal presynaptic terminals. Recent evidence has implicated 
α-Syn in regulating synaptic vesicle release, mobility and recycling 25, 27, along with 
decreased DA release from vesicles in the background of α-Syn overexpression 26. 
Wildtype α-Syn has been shown to inhibit tyrosine hydroxylase (TH) activity, suggesting 
a physiological role in controlling optimal DA biosynthesis 29. However, aggregated 
forms are no longer able to inhibit TH activity, with higher TH phosphorylation present 
251. Studies have found that differential α-
	   45	  
toxins; wildtype or low levels of the protein may be protective against oxidative insults 
109, while high intracellular levels can promote abnormal and pathogenic aggregation of 
the protein 110. Elucidating the wildtype role of α-Syn and its expression levels in the 
background of other PD genes may provide deeper insight into the neuroprotective or 
neurotoxic nature of α-Syn in PD.  
While genes such as SNCA, parkin, pink1 and dj1 may be associated with PD, 
the heterogeneity in age-of-onset, as well as 90% of cases being sporadic in nature, 
warrants investigation into the role of environmental factors in PD etiology. One such 
factor is manganese (Mn). This is an essential trace element that is necessary for 
proper immune function, bone growth, digestion, reproduction, as well as serving as an 
important cofactor for many enzymes 138. However, overexposure can result in 
symptomatology that resembles PD 194, 252. Outside of daily dietary Mn intake through 
various food sources, environmental sources of Mn exposure can include drinking water 
(groundwater), pesticides, manufacturing by-products, and airborne exposure upon 
combustion of the fuel additive methylcyclopentadienyl manganese tricarbonyl (MMT). 
However, excessive occupational Mn exposure may also arise from welding, steel 
mining, smelting, and other industrial occupations 253. Several studies have already 
begun to examine gene-environment interactions between Mn exposure and PD-
associated genes. For example, rats exposed to Mn-containing welding fumes show an 
increase in parkin protein levels 222; Parkin was also shown to selectively protect against 
Mn-induced DAergic cell death in vitro 221. Additionally, significant evidence exists for an 
association between Mn and α-Syn, with several studies finding Mn-induced changes in 
α-Syn expression levels, conformation and aggregation 213, 254.  
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In this work, the tractable, invertebrate Caenorhabditis elegans (C. elegans) 
model system expressing human wildtype α-Syn was used for the first time to examine 
the roles of several early-onset, PD-associated genes (pdr-1, pink-1 and djr-1.1) and α-
Syn in mediating Mn-induced neurotoxicity. We demonstrate a novel role for α-Syn in 
altering Mn accumulation in the background of mutated genes (pdr-1 and djr-1.1) 
through the utilization of inductively coupled plasma-mass spectrometry (ICP-MS/MS), 
as well as visualizing intraworm Mn levels by laser ablation-inductively coupled plasma-
mass spectrometry (LA-ICP-MS). Furthermore, we provide support for a neuroprotective 
role of wildtype α-Syn that may be dependent upon its expression level and only in the 
background of select genes, suggesting distinctive roles for each of the PD genes 
studied in Mn-induced DAergic neurotoxicity. 
 
Materials & Methods 
C. elegans Strains and Handling – C. elegans strains were handled and maintained at 
20°C as previously described 255. The following control strains were used: N2, wildtype 
(Caenorhabditis Genetics Center, CGC); and BY200, pdat-1::GFP(vtIs1) V (kindly 
provided by the Blakely laboratory, Vanderbilt University Medical Center). The following 
deletion mutants were used: VC1024, pdr-1(gk448) III (CGC); pink-1(tm1779) II; and 
djr-1.1(tm918) II. These deletion strains were also crossed with the BY200 strain for 
GFP control studies. The following α-synuclein-containing strains were kindly provided 
by the Caldwell laboratory (University of Alabama): UA44, pdat-1::α-Syn, pdat-
1::GFP[baIn11]; UA88, pdr-1(tm598), pdat-1::α-Syn, pdat-1::GFP[baIn11]; UA84, djr-
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1.1(tm918), pdat-1::α-Syn, pdat-1::GFP[baIn11]; and UA86, pink-1(tm1779); pdat-1::GFP; 
pdat-1::α-Syn [baIn11]. 
 
Preparation of MnCl2 – MnCl2 (>99.995 % purity) (Sigma-Aldrich) stock solutions were 
prepared in 85 mM NaCl. To prevent oxidation, fresh stock solutions were prepared 
shortly before each experiment. 
 
Acute Mn Treatments and Mn-Induced Lethality Assay – 2,500 synchronized L1 worms 
per tube were acutely exposed to MnCl2 in triplicates in siliconized tubes for 30 minutes. 
Worms were then pelleted by centrifugation at 7000 rpm for 3 minutes and washed four 
times in 85 mM NaCl. 30-50 worms were then pre-counted and transferred to OP50-
seeded NGM plates and blinded. 48 hours post-treatment, the total number of surviving 
worms was scored. 
 
Mn Quantification in C. elegans – Mn content was determined after ashing of L1 worms 
by ICP-MS/MS. Briefly, 50,000 synchronized L1 worms were acutely treated with MnCl2. 
Worms were pelleted, washed five times in 85 mM NaCl and re-suspended in 1 mL 85 
mM NaCl supplemented with 1% protease inhibitor. After sonication, an aliquot was 
taken for protein quantification using the bicinchoninic acid (BCA) assay-kit (Thermo 
Scientific). Subsequently, the suspension was mixed again, evaporated, and incubated 
with the ashing mixture (65%HNO3/30%H2O2 (1/1) (both from Merck)) at 95°C for at 
least 12 h. After dilution of the ash with 2% HNO3 including 10 µg/L Rh as internal 
standard to compensate drift effects, the Mn concentration was determined by ICP-
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MS/MS (Agilent 8800 ICP-QQQ). The nebulizer gas flow and parameters of lenses, Q1, 
collision cell and Q2 were tuned daily on a daily basis for maximum sensitivity (an oxide 
ratio of <1.0% (140Ce160+/140Ce+) and a double charged ratio of <1.5% (140Ce++/140Ce+) 
with background counts <0.1 cps) (Supplementary Figures, Table 1). The limit of 
quantification (LOQ) for Mn was 0.10 µg/L calculated according to the 3σ-criterion 256. 
Determinations of blank and certified reference material (CRM 414 (plankton) 
(Community Bureau of Reference of the Commission of the European Communities)) 
were performed periodically after 15 samples each. 
Additionally, the Mn content was qualitatively confirmed by LA-ICP-MS analyses. 
Briefly, 50,000 synchronized L1 worms acutely exposed to MnCl2 were pelleted and 
washed three times with 85 mM NaCl and two times with bidistilled water. Worms were 
prepared for analyses by drying single worms on microscopic slides (Thermo Scientific).  
The laser ablation system LSX213G2+ (CETAC Technologies) was coupled to an ICP-
MS (ICAP Qc, Thermo Fisher Scientific). Slides were placed in the ablation chamber 
and ablated linewise using a quintupled Nd:YAG laser (wavelength 213 nm, repetition 
frequency 20 Hz spot, spot diameter 4 µm). The ablated material was transported into 
the ICP-MS by the carrier gas (He/Ar) and analytes were determined using the MS in 
KEDS mode (Supplementary Figures, Tables 2 & 3). In addition, a 10 µg/L Rh-
solution including 2% HNO3 was continuously delivered into ICP via a cyclonic 
spraychamber to compensate drift effects during analysis. 
 
RONS Measurement – The formation of reactive oxygen and nitrogen species (RONS) 
in whole L1 worms was evaluated by a 5(&6)-Carboxy-2`,7`-dichlorodihydrofluorescein-
	   49	  
diacetate (carboxy-DCFH-DA)-based plate reader system. Briefly, a carboxy-DCFH-DA 
stock solution (50 mM in DMSO) (Invitrogen) was diluted 1:100 with M9 buffer, and 
synchronized L1 worms were exposed to 500 µM for 1 h in the dark. After 1 h, the 
worms were washed two times with M9 buffer and two times with 85 mM NaCl to 
remove all carboxy-DCFH-DA content outside the worm. 10,000 worms were 
transferred to each well of a 96 well plate and incubated with H2O2 (positive control) or 
MnCl2 (respective LD25 concentration). Immediately after incubation, the intracellular 
oxidation of carboxy-DCFH, which correlates with intracellular RONS, was monitored 
(excitation 485 nm/emission 535 nm) by a microplate reader (FLUOstar Optima 
microplate reader, BMG Labtechnologies), and kinetics were constructed up to 420 min. 
To exclude interfering fluorescence of the matrix, data were normalized to a control 
(dye-loaded cells without a RONS generator).  
 
Glutathione Quantification – Total intracellular glutathione levels (reduced and oxidized 
GSH) have been determined using the “enzymatic recycling assay”, as previously 
described 257, 258. Briefly, whole worm extracts were prepared out of 50,000 L1 worms 
acutely exposed to MnCl2. This was followed by washes with 85 mM NaCl and 
sonication of the pellet in 0.1 mL ice-cold extraction buffer (1% Triton X-100, 0.6% 
sulfosalicylic acid) and 1% protease inhibitor in KPE buffer (0.1 M potassium phosphate 
buffer, 5 mM EDTA). Intracellular GSH was quantified by measuring the change in 
absorbance per minute at 412 nm by a microplate reader after reduction of 5,5′-dithio-2-
nitrobenzoic acid (DTNB, Sigma-Aldrich). 
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TaqMan Gene Expression Assay – Total RNA was isolated via the Trizol method. 
Briefly, following treatment, 1 mL of Trizol (Life Technologies) was added to each tube 
containing worms resuspended in 100 µl 85 mM NaCl, followed by three cycles of 
freezing in liquid nitrogen and thawing at 37°C. 200 µL of chloroform was then added to 
each tube, followed by precipitation using isopropanol and washing with 75% ethanol. 
Following isolation, 1 µg total RNA was used for cDNA synthesis using the High 
Capacity cDNA Reverse Transcription Kit (Life Technologies), per manufacturer’s 
instructions. cDNA samples were stored at 4°C. Quantitative real-time PCR (BioRad) 
was conducted in duplicate wells using TaqMan Gene Expression Assay probes (Life 
Technologies) for each gene, using the afd-1 (actin homolog) housekeeping gene for 
normalization after determining the fold difference using the comparative 2−ΔΔCt method 
259. The following probes were used: human SNCA (Assay ID: Hs01103383_m1); dat-1 
(Assay ID: Ce02450891_g1); skn-1 (Assay ID: Ce02407447_g1); and afd-1 (Assay ID: 
Ce02414573_m1). 
 
Dopaminergic Degeneration Assay – 2,500 synchronized L1 worms per tube were 
acutely exposed to MnCl2. Upon washing, all worms were plated on OP50-seeded NGM 
plates. 48 hours post-treatment, 50 worms were transferred to fresh OP50-seeded NGM 
plates and blinded for subsequent imaging. At 72 hours post-treatment, 15 worms per 
condition were mounted onto 4% agar pads (in M9 buffer) and anesthetized with 0.2% 
tricaine/0.02% tetramisole in M9 buffer. Scoring of neuronal defects was performed 
using an epifluorescence microscope (Nikon Eclipse 80i) equipped with a Lambda LS 
Xenon lamp (Sutter Instrument Company) and Nikon Plan Fluor 20x dry and Nikon Plan 
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Apo 60x 1.3 oil objectives. Each worm was scored for the absence (“normal”) or 
presence of any of the following morphological changes: puncta formation along 
dendritic processes; shrunken soma; and/or loss of soma and/or dendrites 
(“degenerated”). Representative confocal images (Carl Zeiss MicroImaging, Inc.) of 
each morphological phenotype were taken and processed as previously described 260. 
 
α-Syn Protein Levels  – The α-Syn protein level was quantified by SDS-PAGE/western 
blot analysis as described previously 261, with slight modifications. 150,000 
synchronized L1 worms acutely treated with MnCl2 were washed three times with 85 
mM NaCl. Afterwards, the worm pellet was re-suspended on ice in lysis buffer (RIPA 
buffer (Sigma-Aldrich), 1% protease inhibitor), and the worm pellets were temporarily 
frozen in liquid nitrogen. The extracts were homogenized by sonication and 
centrifugation, followed by using an aliquot of the isolated supernatant for protein 
quantification by the BCA assay. 30 µg of the protein sample were separated by 12% 
denaturating SDS-PAGE and transferred to a nitrocellulose membrane (Whatman) by 
tank blotting. Membranes were blocked for 1 h in 5% bovine serum albumin (BSA) in 
Tris buffered saline (TBS) containing 0.1% Tween-20 (TBST). Subsequently, the blots 
were incubated with the primary mouse monoclonal anti-α-Syn antibody (1:500) (#sc-
12767, Santa Cruz Biotechnology) or mouse monoclonal anti-β-actin antibody (1:10000) 
(Sigma-Aldrich) (as loading control) overnight at 4°C. Following incubation with an 
horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h at room 
temperature, the visualization was obtained by LuminataTM forte western HRP substrate 
(Millipore) and detection by a chemiluminescence imaging system (ChemiDoc MP, Bio-
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Rad). Protein levels were quantified by densitometric analysis with ImageJ software 
(National Institute of Health) and normalized to controls. 
 
Statistics – Dose-response lethality curves and all histograms were generated using 
GraphPad Prism (GraphPad Software Inc.). A sigmoidal dose-response model with a 
top constraint at 100% was used to draw the lethality curves and determine the 
respective LD50 values (values represent the respective Mn concentrations that induce 
50% reduction in survival), followed by a one-way analysis of variance (ANOVA) with a 
Dunnett’s post-hoc test to compare all strains to their respective control strains. In order 
to compare all α-Syn to non-α-Syn-containing strains, a one-way ANOVA using 
Bonferroni’s multiple comparison post-hoc test was conducted.  Two-way ANOVAs 
were performed on metal content, RONS, GSH, TaqMan gene expression and western 
blot densitometry data, followed by Bonferroni’s multiple comparison post-hoc tests. 
Degeneration data was plotted as a stacked histogram and analyzed using an unpaired 
t-test between groups (vs. respective control strains). 
 
Results 
pdr-1 mutants are hypersensitive to acute Mn exposure – Assessment of dose-
response survival curves following acute Mn exposure revealed a leftward-shift in the 
curve for pdr-1 mutant worms compared to N2 wildtype (WT) worms (Fig 4A). Thus, 
pdr-1 mutants exhibited hypersensitivity to Mn-induced lethality (LD50 = 5.59 mM) 
compared to WT worms (LD50 = 10.43 mM). However, djr-1.1 mutants were less  
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Figure 4. pdr-1 mutants are hypersensitive to an acute Mn exposure. (A,B) Dose-response survival 
curves following acute Mn exposure and the respective LD50 doses. All values were compared to non-
treated worms set to 100% survival and plotted against the logarithmic scale of the used Mn 
concentrations. (A) N2 (wildtype, WT) and pdr-1, pink-1 and djr-1.1 deletion mutants were treated for 30 
min at L1 (larval) stage with increasing concentrations of MnCl2. (B) UA44 (WT; human α-Syn), UA88 
(pdr-1 KO; human α-Syn), UA86 (pink-1 KO; human α-Syn) and UA84 (djr-1.1 KO; human α-Syn) were 
treated for 30 min at L1 stage with increasing concentrations of MnCl2. (A,B) Data are expressed as 
means ± SEM from at least four independent experiments. Statistical analysis of the LD50: **p < 0.01 
versus respective wildtype worms. (C) Statistical comparison of respective non-α-Syn and α-Syn 
containing worms: *p < 0.05. KO = deletion mutants. 
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sensitive to acute Mn exposure vs. WT worms. Of the two djr-ortologues, the djr-1.1 
shows the highest homology to vertebrate dj1 and broadest expression (similar to the 
other deletion mutants) 101, 262. Therefore, all studies were carried out in the djr-1.1 
orthologue. Treating worms containing human WT α-Syn in addition to the respective 
genetic deletions (pdr-1, pink-1 and djr-1.1) with Mn led to increased sensitivity 
compared to the WT α-Syn control strain (Fig 4B). One-way ANOVA analysis 
(comparing data from fig. 1A and B) showed a significantly increased sensitivity of the 
α-Syn-containing djr-1.1 mutants compared to the djr-1.1 mutants alone (Fig 4C). 
 
Enhanced Mn accumulation in pdr-1 and djr-1.1 mutants is attenuated by WT α-Syn 
expression - To determine whether a genetic deletion and/or the presence of WT α-Syn 
alters Mn bioavailability in C. elegans, Mn content was measured by ICP-MS/MS. 
Overall, the analyzed strains (Fig 5A, B) showed a dose-dependent increase in Mn 
content (two-way ANOVA, concentration p < 0.0001). The pdr-1 and djr-1.1 deletion 
mutants exhibited an enhanced Mn accumulation compared to WT worms (fig. 5A). 
pink-1 mutants showed Mn accumulation that was indistinguishable from WT worms (fig. 
5A). Notably, the pdr-1 and djr-1.1 mutants containing α-Syn accumulated less Mn 
compared to the respective deletion mutants alone (Fig 5C, D). While the rescue effect 
was not significant for the pdr-1 mutants (Fig 5C), the decrease in accumulation was 
significant at 7.5 and 10 mM Mn for the djr-1.1 mutants (Fig 5D). Moreover, we 
qualitatively confirmed the intraworm Mn accumulation using LA-ICP-MS. WT and djr-
1.1 mutants, with and without α-Syn, were treated acutely with LD50 dose (10 mM) (Fig  
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Figure 5. Enhanced Mn accumulation in pdr-1 and djr-1.1 mutants is reversed by WT α-Syn 
expression. (A-D) Intraworm Mn content after acute treatment with MnCl2 was quantified by ICP-MS/MS. 
All values were normalized to non-treated wildtype (WT) worms. (A) N2 (WT) and pdr-1, pink-1 and djr-
1.1 deletion mutants were treated at L1 stage for 30 min with increasing concentrations of MnCl2. (B) 
UA44 (WT; human α-Syn), UA88 (pdr-1 KO; human α-Syn), UA86 (pink-1 KO; human α-Syn) and UA84 
(djr-1.1 KO; human α-Syn) were treated at L1 stage for 30 min with increasing concentrations of MnCl2. 
(C) Comparing intraworm Mn content of pdr-1 mutants and UA88 (pdr-1 KO; human α-Syn) after 30 min 
treatment with MnCl2 (data from A,B). (D) Comparing intraworm Mn content in djr-1.1 mutants and UA84 
(djr-1.1 KO; human α-Syn) after 30 min treatment with MnCl2 (data from A,B). (A-D) Data are expressed 
as means + SEM from at least six independent experiments. Statistical analysis by two-way ANOVA: (A) 
interaction p < 0.001, genotype p < 0.001, concentration p < 0.001; (B) interaction ns, genotype p < 
0.001, concentration p < 0.001; (C) interaction ns, genotype ns, concentration p < 0.001; (D) interaction p 
< 0.001, genotype p < 0.001, concentration p < 0.001. ***p < 0.001, **p < 0.01, *p < 0.05. (E) 2D images 
and respective microscope images of WT worms (I, non-treated; II, 10 mM MnCl2); djr-1.1 deletion 
mutants (III) and UA84 (djr-1.1 KO; human α-Syn) (IV) incubated with 10 mM MnCl2 for 30 min. KO = 
deletion mutants; ns = not significant. 
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4). The images corroborate the ICP-MS/MS metal content analyses, showing increased 
Mn accumulation in the djr-1.1 mutants compared to the α-Syn-containing djr-1.1 
mutants (Fig 5E).  
 
Mn-induced oxidative stress is exacerbated in pdr-1 and djr-1.1 mutants, but rescued by 
α-Syn expression - Oxidative stress is implicated in Mn-induced neurotoxicity 263. 
Additionally, parkin, pink1 and dj1 are all involved in regulating oxidative stress 
pathways264. Therefore, we investigated the relationship between Mn and their oxidative 
stress and defense responses by measuring the presence of RONS and total GSH 
levels. In order to determine the presence of RONS in whole worms, a carboxy-DCFH-
DA based reader test system was established (data not shown). Figure 6A shows Mn-
induced RONS levels in WT worms, pdr-1 and djr-1.1 mutants, along with their 
respective α-Syn-containing strains. In response to sub-lethal, acute Mn treatment 
(respective LD25), WT worms showed a time-dependent increase in Mn-induced RONS 
that was exacerbated in pdr-1, pink-1 and djr-1.1 mutants (data are normalized to 
respective control (dye-loaded cells without a RONS generator) at each respective 
timepoint). As illustrated in Fig 6A (c & d), pdr-1 and djr-1.1 mutants containing α-Syn 
showed a lower Mn-induced RONS level compared to the non α-Syn containing deletion 
mutants.   
Next, the redox status of the deletion mutants was examined by measuring total 
GSH levels. Notably, the deletion mutants contained significantly less total GSH than 
the WT worms (Fig 6B). Mn treatment resulted in a slight reduction of GSH levels, 
which did not attain statistical significance. The significant decrease at 10 mM Mn in the  
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Figure 6. Mn-induced oxidative stress is exacerbated in pdr-1 and djr-1.1 mutants, but rescued by α-
Syn expression. (A) (a) Effect of MnCl2 on the RONS induction in N2 (WT) and pdr-1, pink1 and djr-1.1 
deletion mutants after 1 h dye loading and subsequent MnCl2 post-treatment with their respective LD25 
doses. (b) Effect of MnCl2 on the RONS induction of UA44 (WT; human α-Syn), UA88 (pdr-1 KO; human 
α-Syn), UA86 (pink1 KO; human α-Syn) and UA84 (djr-1.1 KO; human α-Syn) after 1 h dye loading and 
subsequent MnCl2 post-treatment with their respective LD25 doses. (c) Comparing Mn-induced RONS 
induction of pdr-1 mutants and UA88 (pdr-1 KO; human α-Syn) (see B,a and B,b). (d) Comparing Mn-
induced RONS induction of djr-1.1 mutants and UA84 (djr-1.1 KO; human α-Syn) (see B,a and B,b). (A) 
Shown are mean values (+ SEM) of at least four measurements, which were normalized to the respective 
dye-loaded worms at the respective time-point. Statistical analysis by two-way ANOVA: (a,b,c) interaction 
p < 0.001, genotype p < 0.001, time p < 0.001; (d) interaction ns, genotype p < 0.001, time p < 0.001. (B) 
Total glutathione level of N2 (WT) and pdr-1, pink1 and djr-1.1 deletion mutants following 30 min 
exposure with increasing concentrations of MnCl2. Data are expressed as means + SEM from at least five 
independent experiments. Statistical analysis by two-way ANOVA: interaction ns, genotype p < 0.001, 
concentration p < 0.01. (A-C) p < 0.001. ***p < 0.001, **p < 0.01, *p < 0.05. KO = deletion mutants; ns = 
not significant. 
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pdr-1 mutants may be due to their Mn-induced lethality at this dose (Fig 4A). The α-
Syn-containing deletion mutants showed similar effects as the deletion mutants alone 
(data not shown). Treatment with H2O2 as a positive control confirmed further that the 
inherently decreased levels of GSH in the mutants represent an innately defective 
oxidative stress response, as H2O2 treatment did not significantly alter the GSH levels 
from baseline levels as compared to WT worms (data not shown).  
 
Increased skn-1 mRNA expression in djr-1.1 and pink-1 mutants – To determine 
whether the differences in oxidative stress levels are associated with differences in 
cellular defense responses against oxidative stress, expression of the antioxidant 
response gene skn-1, the orthologue of the vertebrate gene nrf2265, was examined. 
Gene expression data reveal inherently upregulated skn-1 mRNA levels in the deletion 
mutants compared to WT worms (Fig 7A), reaching statistical significance in the pink1 
and djr-1.1 mutants. Acute Mn treatment resulted in an upregulation of skn-1 mRNA at 
the LD50 dose only in djr-1.1 mutants. Interestingly, the pdr-1 mutants containing α-Syn 
showed a slight, but not statistically significant, increase in skn-1 mRNA expression vs. 
WT animals containing α-Syn, whereas the levels were decreased in the pink-1 and djr-
1.1 mutants (Fig 7B).  
 
DAergic neurodegeneration in WT and pdr-1 mutants is attenuated by α-Syn expression 
– Next, we determined whether α-Syn expression would ameliorate or exacerbate DA 
neurodegeneration in the deletion mutants upon acute Mn exposure. Visualization of the  
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Figure 7. Increased skn-1 mRNA expression in djr-1.1 and pink-1 mutants - SKN-1 expression after 
acute treatment with MnCl2. Relative gene expression was determined by qRT-PCR. (A) N2 (WT) and 
pdr-1, pink-1 and djr-1.1 deletion mutants were treated at L1 stage for 30 min with MnCl2 at the respective 
LD25 and LD50 doses. (B) UA44 (WT; human α-Syn), UA88 (pdr-1 KO; human α-Syn), UA86 (pink-1 KO; 
human α-Syn) and UA84 (djr-1.1 KO; human α-Syn) were treated at L1 stage for 30 min with MnCl2 at the 
respective LD25 and LD50 doses. (A, B) Shown are mean values ± SEM of four independent experiments 
in duplicates normalized to the untreated wildtype and relative to afd-1/β-actin mRNA. Statistical analysis 
by two-way ANOVA: (A) interaction ns, genotype p < 0.01, concentration; (B) interaction ns, genotype ns, 
concentration ns. **p < 0.01, *p < 0.05 versus respective wildtype worms. KO = deletion mutants; ns = not 
significant. 
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architecture of the four cephalic (CEP) dopaminergic (DAergic) neurons in the head was 
performed using worms expressing green fluorescent protein (GFP) under the control of  
a promoter for the dopamine re-uptake transporter 1 (C. elegans orthologue for 
vertebrate DAT226), pdat-1::GFP (vtIs1). Using an objective scoring system, the CEP 
neurons were scored as degenerated if they exhibited any of the following: 
discontinuous, punctated GFP signal in the dendrites (Fig 8A, II); shrinkage of the cell 
body (Fig 8A, III); and/or, ultimately, total loss of soma and/or dendritic GFP signal (Fig 
8A, IV). Mn treatment did not significantly increase the inherent DAergic 
neurodegeneration in WT worms and deletion mutants (Fig 8C, a-c). Interestingly, the 
expression of α-Syn significantly attenuated the DAergic neurodegeneration in 
untreated WT worms and pdr-1 mutants, and following acute Mn treatment at their 
respective LD50. However, this effect was absent in the djr-1.1 deletion mutants, as no 
significant change in DAergic neurodegeneration was noted in the α-Syn-containing djr-
1.1 mutants compared to the djr-1.1 deletion mutants alone.  
 
Increased α-Syn and decreased dat-1 expression in djr-1.1 deletion mutants - 
Prominent theories on PD-associated neurodegeneration implicate the role of α-Syn 
expression. Accordingly, SNCA mRNA and α-Syn protein levels were evaluated in the 
pdr-1 and djr-1.1 deletion mutants. To quantify the transcriptional level of SNCA, qRT-
PCR was performed. Whereas SNCA mRNA expression in the untreated pdr-1 mutants 
was slightly downregulated (not significant), it was inherently increased in the djr-1.1 
deletion mutants compared to WT worms. An acute Mn treatment at its respective LD50 
further enhanced the increased mRNA expression level in the djr-1.1 mutants compared  
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Figure 8. DAergic neurodegeneration in WT and pdr-1 mutants is attenuated by α-Syn expression – (A) 
Representative confocal images used in the scoring system: normal worms (I), worms showing puncta 
(II), shrunken soma (III) or loss of dendrites and soma (IV). (B) The CEP architecture of 15 worms per 
group of WT, pdr-1 and djr-1.1 mutants and the respective α-Syn-containing strains (UA44, UA86, UA88) 
were scored 72 hours after an acute, 30 min treatment with MnCl2. Shown are mean values + SEM of at 
least four experiments each. *p < 0.05 versus respective non-treated worms without α-Syn. KO = deletion 
mutants; ns = not significant. 
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to WT worms (Fig 9A). Furthermore, western blot experiments corroborated these 
results, showing increased α-Syn protein levels (Fig 9B). The α-Syn protein level was 
slightly reduced in pdr-1 mutants, though not reaching statistical significance. Mn 
treatment with the respective LD50 resulted in a significant reduction of α-Syn protein  
levels in the pdr-1.1 mutants compared to untreated WT worms. Notably, the djr-1.1 
mutants showed a Mn-induced increase in α-Syn protein levels corresponding to the 
gene expression data. pink-1 mutants were indistinguishable from the WT in α-Syn 
gene expression and protein level (data not shown).  
We further investigated possible interactions between α-Syn and the dopamine 
transporter (DAT), the protein responsible for synaptic DA clearance. Recent evidence 
points to α-Syn-mediated modulation of DAT as a potential mechanism behind the 
selectivity towards DAergic cell death in PD by decreasing DAT function to alter DAergic 
neurotransmission266. Using Real Time RT PCR, we show that pdr-1 mutants have 
inherently higher dat-1 mRNA levels, whereas the expression is reduced in both treated 
and untreated djr-1.1 mutants compared to WT worms (Fig 9C). pink-1 mutants were 
indistinguishable from the WT worm with respect to DA neurodegeneration and dat-1 
mRNA level (data not shown). 
 
Discussion 
The specific interactions between environmental factors and various genetic deletions 
associated with PD pathophysiology remain poorly understood. In the present study, the 
invertebrate C. elegans model system was used to examine the effects of acute Mn 
exposure on DAergic neurotoxicity in the background of three PD-associated genes  
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Figure 9. Increased α-Syn expression in djr-1.1 deletion mutants - (A) SNCA mRNA expression after 
acute treatment with MnCl2. Relative gene expression was determined by qRT-PCR. UA44 (WT; human 
α-Syn), UA88 (pdr-1 KO; human α-Syn)) and UA84 (djr-1.1 KO; human α-Syn) were treated at L1 stage 
for 30 min with MnCl2 at the respective LD50. Data are expressed as means + SEM from at least four 
independent experiments in duplicates normalized to the untreated wildtype and relative to afd-1/ β-actin 
mRNA. Statistical analysis by two-way ANOVA: interaction ns, genotype p < 0.001, concentration p < 
0.05. **p < 0.01, *p < 0.05 versus respective wildtype worms. (B) Effect of MnCl2 on α-Syn protein level. 
UA44 (WT; human α-Syn), UA88 (pdr-1 KO; human α-Syn)) and UA84 (djr-1.1 KO; human α-Syn) were 
treated for 30 min at L1 stage with MnCl2 at the respective LD50. Subsequently, extracts were prepared 
and western blotting was performed. Shown is one representative western blot in (B,b). Shown are mean 
values + SEM of six independent experiments normalized to β-actin and to the untreated wildtype. 
Statistical analysis by two-way ANOVA: interaction ns, genotype p < 0.001, concentration ns. (C) dat-1 
mRNA expression after acute treatment with MnCl2. Relative gene expression was determined by qRT-
PCR. UA44 (WT; human α-Syn), UA88 (pdr-1 KO; human α-Syn)) and UA84 (djr-1.1 KO; human α-Syn) 
were treated at L1 stage for 30 min with MnCl2 at the respective LD50. Data are expressed as means + 
SEM from at least four independent experiments in duplicates normalized to the untreated wildtype and 
relative to afd-1/β-actin mRNA. Statistical analysis by two-way ANOVA: interaction ns, genotype p < 
0.001, concentration ns. ***p < 0.001, **p < 0.01, *p < 0.05 versus respective wildtype worms. KO = 
deletion mutants; ns = not significant. 
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(pdr-1/parkin, pink-1/pink1 and djr-1.1/dj1) in the absence or presence of wildtype 
human α-Syn, a pathological PD hallmark. The ease in genetic manipulation and 
breeding of nematodes allowed for the quick generation and assessment of crosses 
needed to evaluate DAergic neurodegeneration. Moreover, this model system allows for 
an alternative approach to otherwise time-consuming and costly vertebrate models that  
contain intricate nervous systems, hindering more rapid investigations into 
neurodegenerative mechanisms.  
 As the pdr-1 mutants showed the highest sensitivity to acute Mn exposure, we 
examined whether they showed a differential Mn accumulation profile compared to WT 
worms. Interestingly, both pdr-1 and djr-1.1 mutants displayed significantly enhanced 
intraworm Mn accumulation, as shown by ICP-MS/MS. Mn accumulation inside the 
worms (and not just a measurement of metals bound to the outer worm cuticle) was 
also corroborated by the novel and optimized utilization of LA-ICP-MS267. Recently, our 
laboratory identified a network of Mn transporter genes responsible for controlling Mn 
homeostasis in worms. The smf1-3 genes are orthologues for the mammalian divalent 
metal transporter 1 (DMT1), with SMF-3 serving as the primary Mn uptake transporter in 
C. elegans 241. Interestingly, evidence has pointed to parkin-dependent, proteasomal 
degradation of DMT1 levels in vitro 170. As the pdr-1 gene shows conservation of its 
ubiquitin ligase activity in nematodes, one could hypothesize that the loss of pdr-1 
enhanced Mn uptake due to an increase in SMF-3 expression from the lack of pdr-1-
mediated degradation. This interaction would be interesting to examine in this model 
system, as the C. elegans genome does not have nearly as many E3 ubiquitin ligases 
	   65	  
as the human genome 268, reducing the amount of compensatory mechanisms that may 
be possible in vertebrate knockout models.  
Furthermore, previous evidence in Drosophila melanogaster has shown 
increased lifespan in parkin-null flies upon exposure to metal chelators compared to 
controls, indicating a heightened sensitivity to endogenous copper (Cu2+) and iron (Fe2+) 
levels 269. This interaction was further supported by evidence showing a rescue of the 
parkin null phenotype by overexpression of a metal transcription factor (MTF-1) 270. 
However, previous C. elegans studies in pdr-1 mutants found no increased sensitivity 
upon exposure to Fe2+ and Cu2+ 238. Our current findings of enhanced intraworm Mn 
accumulation corroborate a distinctive connection between parkin and metal 
homeostasis that may be Mn-specific, as we have also previously found that the same 
pdr-1 mutants do not show significantly increased methylmercury (MeHg) accumulation 
compared to WT worms237.  
 Due to the close relationship between parkin and DJ1-associated pathways, it is 
possible that they may be directly regulating each other. New evidence suggests a 
novel role for DJ1 in reducing metal-induced cytotoxicity by directly binding metals in 
vitro. While this study found a weaker binding affinity for Mn compared to Cu2+ and 
mercury (Hg2+) 271, the alterations in Mn homeostasis in the worms may result in 
subsequent intracellular dyshomeostasis of other metals that DJ1 would typically 
sequester. Therefore, it is feasible that the enhancement in Mn accumulation in djr-1.1 
mutants could be due to the lack of metal binding in these animals. Notably, both pdr-1 
and djr-1.1 mutants showed an analogous increase in Mn accumulation, yet they 
possessed differential neurodegeneration profiles. Parkin has recently been shown to 
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down-regulate DJ1 protein and mRNA levels 272, with parkin knockout mice showing 
increased DJ1 protein levels upon proteasomal inhibition 273. The loss of parkin (pdr-1 in 
our case) itself may be sufficient to cause proteasomal impairment from increased 
oxidative stress and abnormal accumulation of misfolded proteins. Thus, compared to 
the djr-1.1 mutants, the amelioration of metal toxicity in pdr-1 mutants may be due to 
increased expression of djr-1.1 in these animals.   
 While manganism is distinctive from PD in terms of the initial site of metal 
accumulation and toxicity (globus pallidus), both medical conditions implicate enhanced 
oxidative damage. In the absence of genetic alterations, Mn itself can cause 
mitochondrial damage by inhibiting complex I of the electron transport chain (ETC) and 
oxidative phosphorylation 158. Mn can also increase isoprostane (lipid peroxidation 
marker) generation and decrease ATP levels in a dose-dependent manner, resulting in 
increased neurodegeneration 263. The increased intraworm Mn concentrations may also 
influence iron (Fe) concentrations, another heavy metal that competes with Mn for 
transport via DMT1 and the transferrin receptor (TfR) 274. Furthermore, Fe has been 
implicated in PD by promoting oxidative damage via the Fenton reaction or altering 
oxidative response pathways 186, 217. Mn has also been shown to exacerbate DA 
oxidation to produce damaging, reactive DA intermediates 214, 275. The combination of 
Mn’s own oxidative potential and enhancement of DA oxidation, represents a plausible 
mechanism for its selectivity towards DAergic neurodegeneration, and it has been 
previously corroborated in C. elegans 260. 
The marked increase in baseline RONS induction in the pdr-1 mutants was 
striking; however, this is not surprising, as parkin’s significant role in mediating 
	   67	  
mitophagy warrants impaired mitochondrial integrity in its absence 35, 276. The similarly 
elevated basal RONS levels in the djr-1.1 mutants do not quite reach the level of the 
pdr-1 mutants. As noted earlier, several studies have affirmed DJ1’s role as an oxidative 
stress sensor, indicating that loss of DJ1 would inherently result in an increased RONS 
production 99. In the context of this particular assay in C. elegans, Mn treatment in WT 
animals does not seem to dramatically increase DCF fluorescence over time (data not 
shown). Thus, we hypothesize that the inherently enhanced RONS induction in pdr-1 
and djr-1.1 mutants reflects a ceiling effect that limits further exacerbation upon acute 
Mn exposure. Given its role in recruiting parkin to damaged mitochondria, it was 
somewhat unexpected that pink-1 mutants only showed a slightly enhanced RONS 
induction compared to WT worms. However, the presence of DJ1 in Drosophila is able 
to rescue mitochondrial deficits in the background of pink1, but not parkin loss 107. This 
could account for the lack of an oxidative stress phenotype in the pink-1 mutants, as 
well as the fact that these mutants did not take up as much Mn as the pdr-1 and djr-1.1 
mutants. 
While a trend was apparent towards a dose-dependent effect of Mn on GSH 
depletion in WT animals, the deletion mutants show no significant change with 
treatment. In particular, the baseline reduction in GSH levels in all deletion mutants 
suggests an inherently impaired ability to adapt to stressful stimuli, such as acute Mn 
exposure. This GSH reducation may also relate to the inherently high levels of RONS 
production in pdr-1 mutants, as they show the lowest basal total GSH levels. Moreover, 
it has been shown that knocking down pink1 in human neurons results in GSH reduction 
264. Similarly, DJ1 expression promotes upregulation of glutathione synthesis 277, which 
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corresponds with the finding in djr-1.1 mutants, showing decreased GSH levels. Taken 
together, our data suggest a possible mechanism of neurotoxicity through compromised 
clearance of Mn-damaged mitochondria due to the loss of an intact Parkin/PINK1/DJ1 
pathway, resulting in heightened RONS production that either cannot be inherently 
combated due to basal GSH deficiencies in the mutants, or is resulting in GSH 
consumption.  
The observed increase in RONS induction and basal GSH depletion in mutants, 
showing enhanced Mn accumulation (pdr-1 and djr-1.1) warranted further examination 
into whether these animals also have alterations in skn-1 expression, the worm 
orthologue for nrf2. Nuclear factor erythroid 2-related factor 2, or Nrf2, is a transcription 
factor that promotes the upregulation of antioxidant genes upon oxidative-stress-
induced translocation from the cytoplasm to the nucleus 278, 279. Previous work has 
found skn-1 mutants to be vulnerable to oxidative stress 280. While not significant, pdr-1 
mutants showed a trend for increased skn-1 mRNA expression, which was consistent 
with increased Nrf2 activity found in an induced pluripotent stem cell (iPSC) study in 
patients harboring parkin mutations 281. Moreover, contrary to DJ1 acting as an Nrf2 
stabilizer 106, we found significantly increased skn-1 mRNA expression in the djr-1.1 
mutants. While we did not expect this increase, there may be a compensatory 
mechanism in these animals to counteract the basal GSH depletion that would 
otherwise protect against RONS production by upregulating skn-1-mediated antioxidant 
gene transcription.   
Although α-Syn is known to be involved in the pathogenesis of PD, its role in both 
neuroprotection and neurodegeneration is controversial. Overexpression of α-Syn, as 
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well as its mutated forms (A30P, E46K, A53T), has been reported to be neurotoxic, 
while WT α-Syn has been implicated to be neuroprotective 109, 282, 283. α-Syn is a 
neuronal protein in vertebrates that is ubiquitously expressed at high levels in all brain 
regions 284, 285, but it is not expressed in C. elegans. Therefore, worms expressing 
human WT α-Syn were utilized to address the role of α-Syn in the mutated background 
of pdr-1, pink-1 and djr-1.1 with respect to Mn homeostasis, oxidative stress and 
DAergic neurodegeneration.  
There is increasing evidence that α-Syn interacts with metal ions, thereby 
affecting their homeostasis. Initial studies of the potential to bind metals came from the 
ability of certain metals to catalyze α-Syn aggregation 286. Overall, two major types of 
interactions between metals and α-Syn have been reported. In addition to non-specific 
sites of electrostatic interactions, the C-terminus contains a 119DPDNEA motif binding 
site, suggesting that metal binding is driven by both electrostatic interactions and the 
residual structure of the α-Syn C-terminus. The C-terminal low-affinity sites have been 
reported to interact with different metal ions, with copper (Cu) and Fe most intensively 
studied 287, 288. Although the majority of metal ions interact with α-Syn with low affinity, 
the protein possesses high affinity to Cu2+ and Fe3+ at the N-terminal region. 
Modifications by redox-active metal ions may be relevant for the aggregation properties 
of α-Syn 289, 290. A co-incubation of α-Syn with Mn2+ has been reported to induce partial 
folding of the protein and serve as an effective promoter of α-Syn aggregation 254.  
In addition to its metal binding capacity, the role of α-Syn as a cellular 
ferrireductase has been recently identified, providing further evidence towards the 
multiple roles of α-Syn in metal homeostasis 291. One very important outcome of the 
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present work is the novel role of α-Syn in altering Mn accumulation in the background of 
mutated pdr-1 and djr-1.1 worms, which may be partially due to an endogenous metal 
binding capacity. Even as α-Syn was only expressed in the DAergic neurons of the 
worms, the global alterations in Mn homeostasis were drastic; secretion of α-Syn into 
other regions cannot be excluded 292, 293. In fact, an environmental toxin (i.e. rotenone) 
has been shown to promote the release of α-Syn from enteric neurons 294.  
In terms of the role of α-Syn in modulating oxidative stress responses, the loss of 
pdr-1 or djr-1.1 in α-Syn-expressing worms resulted in reduced Mn-induced RONS 
production, compared to worms containing the genetic deletion alone. This effect was 
due to the reduced Mn accumulation in the presence of α-Syn in both pdr-1 and djr-1.1 
deletion backgrounds. Additionally, attenuated oxidative stress, in accordance with the 
neuroprotective role of α-Syn, has been shown in cells expressing WT α-Syn, where 
protection against rotenone and maneb toxicity was conferred by preservation of 
mitochondrial function 109. Additionally, WT α-Syn-expressing cells also showed the 
ability to attenuate decreased intracellular GSH levels upon serum deprivation 295. An 
overexpression of α-Syn has been reported to increase the activity of superoxide 
dismutase (SOD), resulting in reduced oxidative stress 296, 297. The results in the current 
study support the literature in finding a neuroprotective role of wildtype α-Syn against 
oxidative stress.  
The second important outcome of the current study is the role of α-Syn as being 
either neuroprotective or neurotoxic in the background of certain genes. While the 
expression of α-Syn significantly attenuated the DAergic neurodegeneration in WT 
worms and pdr-1 mutants, both basally and following acute Mn treatment, this effect 
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could not be observed in the djr-1.1 deletion mutants. Analyzing the SNCA mRNA 
expression and α-Syn protein level revealed that this effect may be due to differential 
expression levels of α-Syn. The expression is slightly lower (not significant from WT) 
basally in the pdr-1 mutants, consistent with clinical findings that patients with parkin 
mutations do not typically show α-Syn Lewy body deposition 298, 299. However, α-Syn 
mRNA was upregulated by three-fold in the djr-1.1 mutants.  
These differential expression levels of α-Syn might affect neurotransmitter 
release, since one function of α-Syn is the modulation of the dopamine transporter 
(DAT). This transporter (DAT-1 in C. elegans) is involved in synaptic neurotransmitter 
clearance, and especially responsible for DA reuptake to remove excessive extracellular 
DA concentrations 300-302. Inhibition of DAT leads to high extracellular DA levels 303, 304. 
In C. elegans, we have already shown that upon Mn exposure, loss of dat-1 is 
detrimental to worm survival, with extracellular DA exacerbating Mn-induced oxidative 
stress, lifespan reduction and DAergic neurodegeneration 260. Moreover, previous 
observations in α-Syn-overexpressing cells show that increased α-Syn levels induce a 
dose-dependent reduction of DAT function, as hippocampal and DAergic neurons 
expressing two- to threefold WT α-Syn above normal levels (similar to the djr-1.1 
mutants in this study) show impaired neurotransmitter release 305, 306. Remarkably, in 
the present study, pdr-1 mutants showed lower basal α-Syn levels and inherently higher 
dat-1 mRNA levels, corresponding to the reduced DAergic neurodegeneration, thus 
suggesting a neuroprotective role for α-Syn that implicates increased extrasynaptic DA 
clearance. While pdr-1 mutants exposed to Mn showed reduced α-Syn protein levels 
and increased dat-1 mRNA levels (not significant from WT), Mn treatment did not 
	   72	  
attenuate the DAergic neurodegeneration seen in untreated α-Syn-containing pdr-1 
mutants. α-Syn in WT worms and pink-1 mutants showed a similar neuroprotective 
effect. A study in Drosophila pointed out the synergistic effect of expression of α-Syn 
and pink1, allowing for enhanced protection and increased survival 307.  
In contrast to the pdr-1 mutants, the djr-1.1 mutants containing α-Syn showed a 
three-fold upregulation of α-Syn mRNA and downregulation of dat-1 mRNA, suggesting 
reduced synaptic DA clearance. However, these animals did not show an α-Syn-
induced attenuating effect on DAergic neurodegeneration. Mn treatment resulted in 
increased α-Syn expression, consistent with observations that iron is modulating α-Syn 
at the transcriptional level 308. While dat-1 mRNA levels remained reduced, they were 
indistinguishable from the untreated djr-1.1 worms. The DAergic neurodegeneration 
was also indistinguishable from the untreated djr-1.1 animals containing α-Syn. 
Interestingly, the djr-1.1 mutants containing α-Syn showed the same level of 
neurodegeneration as the djr-1.1 deletion mutants alone, yet they showed less Mn 
accumulation; this implicates a more severe phenotype in the α-Syn-containing worms, 
as it took less Mn accumulation to produce the same level of DAergic 
neurodegeneration. The contrast in SNCA mRNA expression between pdr-1 and djr-1.1 
mutants could be explained by post-transcriptional mechanisms that are regulated 
differentially by the two genes. Another possible explanation is promoter competition, as 
α-Syn is sharing the dat-1 promoter, but this has yet to be elucidated. 
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Conclusions 
 The genetically amenable C. elegans model system was utilized to examine the 
neuroprotective or neurotoxic role of α-Syn in mediating Mn neurotoxicity in the 
background of loss in the PD-associated genes pdr-1, pink-1 and djr-1.1. For the first 
time, the current study provides evidence for a neuroprotective role of α-Syn against Mn 
accumulation and Mn-induced oxidative stress in the background of pdr-1 and djr-1.1 
loss. However, its neuroprotective role may be dependent upon its expression level, as 
increased levels in the djr-1.1 mutants were associated with increased DAergic 
neurodegeneration. These findings also support the role of extracellular DA in 
exacerbating Mn neurotoxicity, with decreased dat-1 levels promoting increased 
DAergic neurodegeneration in the djr-1.1 mutants. Collectively, the findings presented in 
this chapter support the overarching hypothesis that the loss of genes associated with 
early-onset PD, namely pdr-1 and djr-1 in C. elegans, results in increased susceptibility 
to Mn toxicity.  
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CHAPTER III 
 
 
LOSS OF PDR-1/PARKIN INFLUENCES MANGANESE HOMEOSTASIS THROUGH 
ALTERED FERROPORTIN EXPRESSION IN C. ELEGANS309 
 
 
 
Introduction 
Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder, with a typical age of onset around 60 years of age121. This debilitating disease 
is characterized by selective dopaminergic (DAergic) cell loss in the substantia nigra 
pars compacta (SNpc) region of the brain. Hallmark symptoms of PD include 
bradykinesia, rigidity, tremors and postural instability that are often preceded by 
emotional instability and cognitive dysfunction. Unfortunately, PD is a progressive and 
irreversible condition1. Current treatments do not target the molecular origins of PD, 
warranting further examination into the mechanisms behind its pathophysiology. 
Though PD is mostly idiopathic in its etiology, mutations in several genes have 
been connected to the disease1. For example, homozygous mutations in the 
PARK2/parkin gene are responsible for nearly 50% of an autosomal recessive, early-
onset form of PD74. This gene encodes for an E3 ubiquitin ligase involved in the 
ubiquitin proteasome system (UPS) that targets substrates for degradation. Mutations in 
this gene result in impaired ligase activity and substrate binding that can lead to 
increased protein aggregation78. Parkin knockout animal models show a variety of PD-
associated phenotypes, including hypokinetic deficits, DAergic cell loss and increased 
extracellular dopamine (DA) in the striatum79, 247. Parkin has also been more recently 
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identified as a key regulator of mitophagy, an intracellular autophagic process designed 
to eliminate damaged mitochondria from the cell35.  
Despite the known genetic associations, familial cases often present with 
heterogeneity in their age-of-onset and symptomatology, in addition to nearly 90% of all 
PD cases manifesting without genetic disturbances310. The idiopathic component of the 
disease suggests a contribution of environmental risk factors in the development of PD. 
One such factor is the heavy metal manganese (Mn), an essential trace element found 
in many food sources consumed daily by humans. Mn serves as a necessary cofactor 
for enzymes involved in several critical processes, including reproduction, metabolism, 
development, and antioxidant responses138. While deficiency is a rare concern, the 
essentiality of Mn is mirrored by its neurotoxicity upon overexposure. Mn poisoning, or 
manganism, typically occurs from occupational exposures in industrial settings, such as 
in welding, where Mn-containing fumes and/or products are abundant196, 252. Mn is also 
found as an antiknock agent methylcyclopentadienyl manganese tricarbonyl (MMT) in 
gasoline, but limited studies currently exist on the impact of Mn release from 
combustion on general human health311, 312. Mn is also found as a component in 
pesticides, making surface runoff from these agricultural uses an additional source of 
overexposure121. Moreover, Mn toxicity can also affect other susceptible populations, 
including ill neonates receiving TPN that is supplemented with a trace element solution 
containing Mn138. Another population at risk of Mn poisoning includes patients suffering 
from hepatic encephalopathy and/or liver failure, as Mn is excreted from the body 
through the biliary system183, 313. On the other hand, individuals with iron (Fe) deficiency 
(e.g., iron deficiency anemia), a highly prevalent nutritional condition, are at risk for 
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increased Mn body burdens. As Mn shares similar transport mechanisms with Fe, 
higher Mn levels are often seen in conditions of low Fe levels314.  
Tight regulation through an intricate system of transport mechanisms helps 
maintain proper Mn homeostasis in cells. The divalent metal transporter 1 (DMT1) 
represents the primary mode of divalent Mn import132. However, Mn efflux remains less 
understood than Mn import. We previously identified ferroportin (FPN), a well-known 
iron (Fe) exporter, as facilitating Mn export in cells and mice173. We have previously 
identified and characterized components of the Mn transport system in the 
Caenorhabditis elegans (C. elegans) model system. This nematode provides an 
attractive, alternative system that has a rapid life cycle, short lifespan, and large brood 
size. Additionally, the well-characterized genome allows for the utilization of various 
genetic mutants for studies. This nematode also conserves all necessary components 
of a fully functional DAergic system, allowing for the study of the effects of PD-
associated genetic loss on the DAergic system. Our previous studies have identified 
SMF-1, SMF-2 and SMF-3 as the C. elegans homologs for DMT1, with SMF3 acting as 
the most DMT1-like homolog in its necessity to regulate Mn uptake241. Thus far, these 
proteins are the only known Mn importers in the worm. Furthermore, the worm contains 
3 homologs for FPN: FPN-1.1, FPN-1.2 and FPN-1.3315. As of now, FPN-1.1 is the only 
known protein that conserves Fe efflux in C. elegans242.  
The overlap in sites of damage and similar symptomatology between manganism 
and Parkinsonism has warranted investigations into potential gene-environment 
interactions. For example, parkin has been shown to selectively protect against Mn-
induced DAergic cell death in vitro221, while rats exposed to Mn-containing welding 
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fumes show increased Parkin protein levels222. Our previous study using C. elegans 
found significantly enhanced Mn accumulation in pdr-1 (parkin homolog) knockout 
worms compared to WT worms246. With the aforementioned relationships between PD-
associated genes and Mn toxicity, we hypothesized that this enhancement is due to an 
alteration in Mn homeostasis, at the level of transport, in the background of pdr-1 loss. 
In the present study, while no significant change in mRNA expression of importers was 
seen, we found a downregulation of fpn-1.1 mRNA. Upon overexpression of this 
exporter in pdr-1 mutants, we found decreased metal levels that were associated with 
improved survival and DA-dependent behavior. Together, our results provide further 
support for altered metal homeostasis as a component of the pathophysiology seen in 
Parkinsonism. 
 
Materials & Methods 
 Plasmid constructs – Full length wildtype (WT) fpn-1.1 with C-terminal FLAG tag was 
PCR amplified using primers 5’-
GGGGACAAGTTTGTACAAAAAAGCAGGCTACATGGCTTGGTTATCCGGAAAAG-3’ and 5’-
GGGGACCACTTTGTACAAGAAAGCTGGGTTTCACTTGTCATCGTCGTCCTTGTAGTCTTCA
AAAGTTGGCGAATCCAAC-3’ from cDNA library which was converted from total RNAs 
isolated from N2 worms (see below). The plasmid was created with Gateway 
recombinational cloning (Invitrogen).  The above PCR product was initially recombined 
with the pDONR221 vector to create the pENTRY clone. Next, the fpn-1.1 pENTRY 
construct was recombined into pDEST-sur-5 vector316, under the promoter of the 
acetoacetyl-coenzyme A synthetase (sur-5) gene. This plasmid was then used to create 
transgenic worms. 
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C. elegans Strains and Strain Construction – C. elegans strains were handled and 
maintained at 20°C as previously described255. Strains used were: N2, wildtype 
(Caenorhabditis Genetics Center, CGC) and VC1024, pdr-1(gk448) III (CGC). The 
MAB326 strain was created by microinjecting Psur-5::fpn-1.1 with pBCN27-R4R3 (Prpl-
28::PuroR, Addgene) and Pmyo-3::mCherry (a gift from Dr. David Miller) into VC1024 
strain. Over three stable lines were generated and analyzed. Representative lines were 
selectively integrated by using gamma irradiation with an energy setting of 3600 rad.  
 
Preparation of Manganese Chloride (MnCl2) – 2M MnCl2 (> 99.995% purity) (Sigma-
Aldrich) stock solutions were prepared in 85 mM NaCl. To prevent oxidation, fresh 
working solutions were prepared shortly before each experiment. The range of 
concentrations used in all experiments is based on Mn dose-response curves recently 
published by our laboratory246.  
 
Mn-Induced Treatments and Lethality Assay – 2500 synchronized L1 worms per group 
were acutely treated with MnCl2 (0-100 mM) in siliconized tubes for 30 minutes. Worms 
were then pelleted by centrifugation at 7000 rpm for 3 minutes and washed four times 
with 85 mM NaCl. 30-50 worms were then pre-counted and transferred to OP50-seeded 
NGM plates in triplicate and blinded. 48 hours post-treatment, the total number of 
surviving worms was scored as a percentage of the original plated worm count.  
 
TaqMan Gene Expression Assay – Total RNA was isolated via the Trizol method. 
Briefly, following Mn treatment, 1 mL of Trizol (Life Technologies) was added to each 
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tube containing 20,000 worms resuspended in 100 µl 85 mM NaCl, followed by three 
cycles of freezing in liquid nitrogen and thawing at 37°C. 200 µL of chloroform was then 
added to each tube, followed by precipitation using isopropanol and washing with 75% 
ethanol. Following isolation, 1 µg total RNA was used for cDNA synthesis using the 
High Capacity cDNA Reverse Transcription Kit (Life Technologies), per manufacturer’s 
instructions. cDNA samples were stored at 4°C. Quantitative real-time PCR (BioRad 
CFX96) was conducted in duplicate wells using TaqMan Gene Expression Assay 
probes (Life Technologies) for each gene, using the gpd-3 (gapdh homolog) 
housekeeping gene for normalization after determining the fold difference using the 
comparative 2−ΔΔCt method259. The following probes were used: smf-1 (Assay ID: 
Ce02496635_g1); smf-2 (Assay ID: Ce02496634_g1); smf-3 (Assay ID: 
Ce02461545_g1); fpn-1.1 (Assay ID: Ce02414545_m1); and gpd-3 (Assay ID: 
Ce02616909_gH). 
 
Metal Quantification – Total intraworm metal content was quantified using inductively 
coupled plasma mass spectrometry (ICP-MS), as previously described246. Briefly, 
50,000 synchronized L1 worms were acutely treated with MnCl2. Worms were then 
pelleted, washed five times with 85 mM NaCl and re-suspended in 1 mL 85 mM NaCl 
supplemented with 1% protease inhibitor. After sonication, an aliquot was taken for 
protein normalization using the bicinchoninic acid (BCA) assay kit (Thermo Scientific). 
Subsequently, the suspension was mixed again, evaporated, and incubated with the 
ashing mixture (65%HNO3/30%H2O2 (1/1) (both Merck)) at 95 °C for at least 12 h. After 
dilution of the ash with bidistilled water, metal levels were determined by ICP-MS/MS.  
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Relative Mitochondrial DNA Copy Number Quantification – Relative mitochondrial DNA 
copy number was quantified using qPCR methods as previously described317, with slight 
modifications. Briefly, 1,000 synchronized L1 worms were treated with MnCl2 for 30 
minutes, following by several washes. Total genomic DNA was then isolated using a 1X 
PCR buffer containing 0.1% Proteinase K, and subjected to the following lysis protocol 
in a thermal cycler (BioRad T100): 65°C for 90 minutes, 95°C for 15 minutes, and then 
hold at 4°C. Following lysis, DNA was diluted to 3 ng/µl, and real time PCR (BioRad 
CFX96) using SYBR Green (BioRad) was performed in triplicate with the following 
primers: nd-1 for mtDNA (forward primer sequence: 5’-
AGCGTCATTTATTGGGAAGAAGAC-3’; reverse primer sequence: 5’-
AAGCTTGTGCTAATCCCATAAATGT-3’) and cox-4 for nuclear DNA (forward primer 
sequence: 5’-GCCGACTGGAAGAACTTGTC-3’; reverse primer sequence: 5’-
GCGGAGATCACC TTCCAGTA-3’). The PCR reaction consisted of: 2µL of template 
DNA, 1µL each of mtDNA and nucDNA primer pairs (400nM final concentration each), 
12.5µL SYBR Green PCR Master Mix and 8.5µL H2O. The following protocol was used: 
50°C for 2 minutes, 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds and 62°C for 
60 seconds. The mitochondrial DNA content relative to nuclear DNA was calculated 
using the following equations: ΔCT = (nucDNA CT – mtDNA CT), where relative 
mitochondrial DNA content = 2 x 2ΔCT.   
 
Glutathione Quantification – Total intracellular glutathione levels (reduced and oxidized 
GSH) have been determined using the “enzymatic recycling assay”, as previously 
described257. Briefly, whole worm extracts were prepared out of 40,000 L1 worms 
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acutely exposed to MnCl2. This was followed by washes with 85 mM NaCl and 
sonication of the pellet in 0.12 mL ice-cold extraction buffer (1% Triton X-100, 0.6% 
sulfosalicylic acid) and 1% protease inhibitor in KPE buffer (0.1 M potassium phosphate 
buffer, 5 mM EDTA). After centrifugation at 10,000 rpm for 10 minutes at 4°C, the 
supernatant was collected, with an aliquot reserved for protein normalization using the 
BCA assay. Total intracellular GSH was quantified by measuring the change in 
absorbance per minute at 412 nm by a microplate reader (FLUOstar Optima microplate 
reader, BMG Labtechnologies) after reduction of 5,5′-dithio-2-nitrobenzoic acid (DTNB, 
Sigma-Aldrich). Hydrogen peroxide was used as a positive control. 
 
Basal Slowing Response Assay – This assay of dopaminergic integrity was performed 
as previously described228, with slight modifications. Briefly, 2500 synchronized L1 
worms were acutely treated in siliconized tubes with MnCl2 for 30 minutes. Following 
washes with 85 mM NaCl, treated worms were transferred to seeded NGM plates. 48 
hours after treatment, 60 mm NGM plates with seeded with bacteria spread in a ring 
(inner diameter of ~1 cm and an outer diameter of ~3.5 cm) in the center of the plate. 
Two seeded and two unseeded plates per group were kept at 37°C overnight, and 
allowed to cool to room temperature before use. Once Mn-treated animals reached the 
young adult stage, animals were washed at least two times with S basal buffer and then 
transferred to the central clear zone of the ring-shaped bacterial lawn (5-10 worms per 
plate) in a drop of S basal buffer that was delicately absorbed from the plate using a 
Kimwipe. After a five-minute acclimation period, the number of body bends in a 20-
second interval was scored for each worm on the plate. Data are presented as the 
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change (Δ) in body bends per 20-second interval between worms transferred to 
unseeded plates and those with bacterial rings. Worms lacking cat-2 (the homolog for 
tyrosine hydroxylase) were used as a positive control, as these worms are impaired in 
bacterial mechanosensation228. General locomotion was assessed using the number of 
body bends/20 seconds of the group transferred to unseeded plates.  
 
Statistics – Dose-response lethality curves and all histograms were generated using 
GraphPad Prism (GraphPad Software Inc.). A sigmoidal dose-response model with a 
top constraint at 100% was used to draw the lethality curves and determine the 
respective LD50 values, followed by a one-way ANOVA with a Dunnett post-hoc test to 
compare all strains to their respective control strains. Two-way ANOVAs were 
performed on TaqMan gene expression, metal content, total GSH, relative mtDNA copy 
number and basal slowing response data, followed by Bonferroni’s multiple comparison 
post-hoc tests. 
 
 Results 
pdr-1 mutants show alterations in mRNA expression of Mn exporter-, but not importer-
related genes – We previously reported a statistically significant increase in Mn 
accumulation in pdr-1 mutants vs. WT worms246. To test whether this enhancement was 
due to a change in transcription of Mn importer and/or exporter genes, we performed 
quantitative reverse transcription PCR (qRT-PCR) to examine smf-1,2,3 (Fig 10A-C) 
and fpn-1.1 gene expression (Fig 10D), respectively, following acute Mn exposure. 
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Figure 10.	   	   pdr-1 mutants show alterations in mRNA expression of Mn exporter, but not importer, 
genes. (A-D) smf-1,2,3 and fpn-1.1 mRNA expression after an acute, 30 min treatment of L1 worms 
with 0, 2.5 and 5 mM MnCl2. Relative gene expression was determined by qRT-PCR. (A) smf-1 
mRNA expression in N2 (WT) and pdr-1 KO animals. (B) smf-2 mRNA expression in N2 (WT) and 
pdr-1 KO animals. (C) smf-3 mRNA expression in N2 (WT) and pdr-1 KO animals. (D) fpn-1.1 mRNA 
expression in N2 (WT) and pdr-1 KO animals. (A-D) Data are expressed as mean values + SEM of at 
least five independent experiments in duplicates normalized to the untreated wildtype and relative to 
gpd3 mRNA. Statistical analysis by two-way ANOVA: (A) interaction, ns; genotype, ns; concentration, 
ns; (B) interaction, ns; genotype, ns; concentration, ns; (C) interaction, ns; genotype, ns; 
concentration, ns; (D) interaction, ns (trend level, p=0.0639); genotype, p<0.0001; concentration, ns. 
*p < 0.05, ***p < 0.001 vs. respective wildtype worms. 
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Two-way ANOVA analysis showed no overall effect of Mn treatment on transcription of 
any of the genes tested. However, while pdr-1 mutants showed no significant changes 
in smf-1,2,3 (the importers) mRNA expression (Fig 10A-C), a significant genotype 
difference (p<0.0001) was noted in fpn-1.1 (the exporter) between pdr-1 mutants and 
WT animals. Post-hoc analysis revealed a significant fpn-1.1 downregulation at 0 and 
2.5 mM MnCl2 (Fig 10D).  
 
Overexpression of fpn-1.1 in pdr-1 mutants rescues Mn-induced lethality – In addition to 
enhanced Mn accumulation, pdr-1 mutants showed a leftward shift in the Mn dose-
response survival curve, with WT worms exhibiting a LD50 of 10.43 mM246. To determine 
whether downregulation of fpn-1.1 may have played a role in exacerbating Mn-induced 
lethality of pdr-1 mutants, we overexpressed fpn-1.1 in the pdr-1 mutant background. 
Upon Mn exposure, pdr-1 mutants overexpressing fpn-1.1 (pdr-1 KO; fpn-1.1 OVR) 
exhibited a rightward shift in the dose-response curve compared to pdr-1 mutants alone 
(Fig 11A). The LD50 of pdr-1 KO; fpn-1.1 OVR animals (10.84 mM) relatively normalized 
to previously published WT levels, while pdr-1 mutants alone show a LD50 of 7.416 mM 
(Fig 11B). Two-way ANOVA analysis showed a significant interaction effect (p=0.0064) 
between both genotype and treatment (p<0.0001). 
 
Overexpression of fpn-1.1 in pdr-1 mutants decreases levels of highly pro-oxidant 
metals   – Upon noting the improved survival in pdr-1 KO; fpn-1.1 OVR animals, we  
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Figure 11. Overexpression of fpn-1.1 in pdr-1 mutants rescues Mn-induced lethality. (A,B) Dose-
response survival curves following acute Mn exposure. All values were compared to untreated worms set 
to 100% survival and plotted against the logarithmic scale of the used Mn concentrations. (A) pdr-1 KO 
animals and pdr-1 mutants overexpressing fpn-1.1 (pdr-1 KO; fpn-1.1 OVR) were treated at the L1 stage 
for 30 min with increasing MnCl2 concentrations. Dashed curve represents the typical WT survival curve 
as previously published. (B) The respective LD50 concentrations (mM MnCl2) for both genotypes. Data are 
expressed as mean values + SEM from at least five independent experiments. Statistical analysis by two-
way ANOVA: interaction, p=0.0064; genotype, p<0.0001; concentration, p<0.0001. 
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hypothesized that this attenuation in Mn-induced toxicity is associated with a decrease 
in redox active metal accumulation. Using inductively coupled plasma mass 
spectrometry (ICP-MS), we measured intraworm concentrations of various metals, 
including Mn, iron (Fe), zinc (Zn) and copper (Cu) following acute Mn exposure. To our 
surprise, Mn levels remained relatively similar between strains, though two-way ANOVA 
analysis revealed a significant treatment effect (Fig 12A, p=0.0165). However, 
endogenous Fe levels were significantly decreased in pdr-1 KO; fpn-1.1 OVR animals 
compared to pdr-1 KOs alone (Fig 12B, p=0.0092), though further significance was not 
reached at the post-hoc level. No significant changes were seen in Zn levels (Fig 12C). 
However, similar to Fe, Cu levels were significantly decreased in pdr-1 KO; fpn-1.1 OVR 
animals compared to pdr-1 KOs (Fig 12D, p=0.0256), with no post-hoc level differences. 
In summary, Mn levels stayed relatively the same, while Fe and Cu were both 
significantly decreased in pdr-1 KO; fpn-1.1 OVR animals. These results indicate that 
the improved survival is probably due to decreased levels of Fe and Cu, and suggests 
that fpn-1.1 may prefer Fe and Cu as substrates over Mn. 
 
Overexpression of fpn-1.1 in pdr-1 mutants improves mitochondrial integrity and 
antioxidant response – Increased Mn levels in pdr-1 KOs (vs. WT animals) have been 
noted concurrently with significantly increased basal levels of RONS and depleted basal 
levels of total glutathione (GSH), suggesting an overall exacerbated environment of 
oxidative stress in pdr-1 KO animals246. Therefore, we next sought to determine whether 
the significant decrease in Fe and Cu levels (Fig 12) and improvement in survival of 
pdr-1 KO;fpn-1.1 OVR animals (Fig 11A) were associated with improved defence  
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Figure 12. Overexpression of fpn-1.1 in pdr-1 mutants decreases levels of highly pro-oxidant metals. 
(A-D) Intraworm metal concentrations following acute, 30 min MnCl2 treatment (0, 2.5 and 5 mM) at the 
L1 stage, as quantified by ICP-MS/MS. (A) Mn content (µg Mn/mg protein) in pdr-1 KO and pdr-1 KO; fpn-
1.1 OVR animals. (B) Iron (Fe) content (µg Fe/mg protein) in pdr-1 KO and pdr-1 KO; fpn-1.1 OVR 
animals. (C) Zinc (Zn) content (µg Zn/mg protein) in pdr-1 KO and pdr-1 KO; fpn-1.1 OVR animals. (D) 
Copper (Cu) content (µg Cu/mg protein) in pdr-1 KO and pdr-1 KO; fpn-1.1 OVR animals. (A-D) Data are 
expressed as mean values + SEM from at least six independent experiments and normalized to total 
protein content. Statistical analysis by two-way ANOVA: (A) interaction, ns; genotype, ns; concentration, 
p=0.0165; (B) interaction, ns; genotype, p=0.0092; concentration, ns; (C) interaction, ns; genotype, ns; 
concentration, ns; (D) interaction, ns; genotype, p=0.0256; concentration, ns. 
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mechanisms against oxidative stress. This was investigated using two measures: 
relative mitochondrial DNA (mtDNA) copy number and total GSH levels. Alterations in 
mtDNA copy number have been associated with aging and degenerative processes318. 
Moreover, parkin has been shown to regulate mitochondrial turnover to maintain proper 
mitochondrial integrity35. Using a quantitative PCR (qPCR) technique, we found pdr-1 
KO animals had a significantly elevated mtDNA copy number relative to WT animals, 
whereas pdr-1 KO;fpn-1.1 OVR animals exhibited levels similar to WT animals (Fig 
13A); two-way ANOVA analysis reveals a significant genotype effect (p=0.0116), though 
significance was not reached at the post-hoc level. Moreover, we previously published 
the basal depletion of total GSH in pdr-1 KOs compared to WT controls. Given the 
reversal of increased mtDNA copy number in pdr-1 KO;fpn-1.1 OVR animals, we 
examined whether there was a similar rescue of GSH depletion. While statistical 
significance wasn’t reached, there was a trend toward increased GSH levels in pdr-1 
KO;fpn-1.1 OVR animals relative to pdr-1 KOs (Fig 13B, p=0.09). In both measures, Mn 
treatment itself did not significantly affect the outcomes.  
 
Overexpression of fpn-1.1 in pdr-1 mutants improves the DA-dependent basal slowing 
response –Loss of parkin is connected to PD-associated DAergic neurodegeneration, 
and we previously published similar results of pdr-1 KOs showing increased DAergic 
neurodegeneration vs. WT worms with fluorescence microscopy246. Consequently, we 
investigated whether the visual effects of DAergic neurodegeneration persisted to alter 
a behavioral outcome of DAergic integrity. The basal slowing response is a DA-
dependent behavior that affects the mechanosensation needed for proper food sensing  
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Figure 13. Overexpression of fpn-1.1 in pdr-1 mutants improves mitochondrial integrity and antioxidant 
response. (A) Relative mitochondrial DNA (mtDNA) copy number in pdr-1 KO and pdr-1 KO; fpn-1.1 OVR 
animals following an acute, 30 min treatment with 0 and 5 mM MnCl2. Relative gene expression was 
determined by qPCR. (B) Total glutathione (GSH) levels of pdr-1 KO and pdr-1 KO; fpn-1.1 OVR animals 
following an acute, 30 min treatment with 0 and 5 mM MnCl2. (A) Relative mtDNA copy number is 
expressed as a ratio of nd-1 (mtDNA marker) to cox-4 (nuclear DNA marker). Data are expressed as 
mean values + SEM of at least five independent experiments in duplicates normalized to the untreated N2 
wildtype values. (B) Data are expressed as mean values + SEM of at least five independent experiments 
in duplicates, normalized to total protein content and relative to untreated pdr-1 KO values. Statistical 
analysis by two-way ANOVA: (A) interaction, ns; genotype, p=0.0116; concentration, ns; (B) interaction, 
ns; genotype, ns (trend level, p=0.09); concentration, ns. 
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in C. elegans, as worms slow their movement when encountering a bacterial lawn. 
Worms lacking cat-2, the homolog for tyrosine hydroxylase, are defective in this 
response from the loss of dopamine synthesis and do not slow down228. Thus, the 
changes (Δ) in number of body bends between plates with and without bacteria reflect 
the integrity of DAergic neurons. Using this paradigm, pdr-1 KO animals exhibited a 
significantly defective basal slowing response vs. WT animals (p<0.001) that was 
analogous to that of cat-2 mutants (Fig 14). The pdr-1 KO;fpn-1.1 OVR animals showed 
a partial rescue of the response, without reaching statistical significance. However, in 
the presence of Mn treatment, pdr-1 KO;fpn-1.1 OVR fully restored the response to WT 
levels, with the changes (Δ) in number of body bends being significantly higher than 
pdr-1 KOs alone (p<0.01). To ensure that these effects were not due to general 
locomotion differences, we compared the number of body bends per group on plates 
without bacterial lawns; there were no significant differences between all groups (Suppl. 
Fig. 1).  
 
Discussion 
 The relationship between genetic mutations and the contribution of 
environmental risk factors in the development of PD has yet to be clearly defined. In the 
present study, the C. elegans model system was utilized to investigate alterations in Mn 
homeostasis and toxicity in animals lacking pdr-1/parkin, a genetic risk factor for PD. 
We previously published evidence that animals lacking pdr-1 show high sensitivity to an 
acute Mn exposure, with decreased survival and significantly elevated Mn accumulation 
compared to WT animals246. The present study aimed to determine whether the  
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Figure 14. Overexpression of fpn-1.1 in pdr-1 mutants improves the DA-dependent basal slowing 
response. Behavioral data are expressed as the change (Δ) in body bends per 20 seconds between 
treated (5 mM MnCl2) and untreated WT, pdr-1 KO and pdr-1 KO; fpn-1.1 OVR animals placed on plates 
without food vs. plates with food. Schematic shows the spectrum of change, with N2 wildtype animals 
possessing a higher change in body bends (i.e., a fully intact DAergic system) to cat-2 mutants 
possessing a smaller, almost negligible change in body bends (i.e., an impaired DAergic system). cat-2 
KO animals were used as a positive control. Statistical analysis by two-way ANOVA: interaction, ns (trend 
level, p=0.0872); genotype, p<0.0001; concentration, ns. ***p<0.001 vs. untreated WT, *p<0.05 vs. pdr-1 
KO. 
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Figure 15. Basic model summarizing the findings of Chapter 3. (A) Loss of pdr-1 results in increased 
Mn accumulation that is associated with downregulation of fpn-1.1 mRNA, increased ROS production, 
basally depleted GSH, elevated mtDNA copy number and deficits in the DA-dependent basal slowing 
response (BSR) vs. WT animals. (B) Upregulation of fpn-1.1 in pdr-1 KO animals ameliorates Mn-induced 
toxicity of pdr-1 KO’s, including slight elevation of GSH, mtDNA copy number and BSR normalization to 
WT levels, and decreased accumulation of Fe, Cu and Mn.  
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enhanced Mn concentrations were due to altered expression of Mn transporters in C. 
elegans to affect Mn homeostasis. Parkin’s role in regulating metal homeostasis has 
only recently begun to be investigated. Previous in vitro evidence has shown that parkin 
can modulate levels of the 1B isoform of DMT1 through ubiquitination170. Moreover, 
Drosophila studies show that both pharmacological (BCS/BPD) or genetic (increased 
expression of the metal responsive transcription factor 1, MTF-1) chelation of redox-
active metals decreases oxidative stress, improves reduced lifespan and normalizes 
metal concentrations in parkin mutant flies269, 270. Therefore, parkin’s regulation of metal 
homeostasis and its role as an E3 ligase raise the possibility of parkin-mediated 
regulation of Mn-responsive proteins. The C. elegans system represents an ideal model 
to study this possibility, as PDR-1 conserves its ligase activity236, and their genome 
contains less E3 ligases319 to minimize the possible compensatory mechanisms seen in 
vertebrate knockout models.  
Contrary to in vitro evidence of parkin-mediated control of a DMT isoform, we 
observed no significant changes in expression of the smf genes, especially with smf-3 
being the most DMT1-like homolog241. Instead, significant downregulation of fpn-1.1 
was observed in pdr-1 KOs compared to WT animals. These findings suggest that the 
loss of pdr-1 in C. elegans results in increased Mn accumulation that may be from 
defective export, rather than from impaired uptake. Notably, we recently identified a 
novel role for SLC30A10 in Mn export that is associated with heightened risk for PD. 
However, no homologs for this protein are expressed in C. elegans177. Thus, for the 
present study, given the downregulation of fpn-1.1 mRNA in pdr-1 mutants, we 
investigated the effects of overexpressing the only known Mn exporter in C. elegans.  
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 Mn uptake is modulated by a variety of proteins, including: DMT1, the transferrin 
receptor (TfR), the choline transporter, the citrate transporter, the magnesium 
transporter HIP14, the P-type transmembrane ATPase (ATP13A2), the solute carrier 39 
family of zinc transporters, and calcium channels252. Among these, DMT1 has been 
given the most attention, as it is not only the primary mode of uptake, but is also 
associated with parkinsonism. Increased DMT1 expression has been found in the SNpc 
of PD patients, as well as in SNpc of MPTP mouse models217. Elevated DMT1 mRNA 
expression and DAergic neurotoxicity was also seen in rats exposed to Mn-containing 
welding fumes320. Moreover, specific polymorphisms in DMT1 have been found in a 
Chinese population suffering from PD218. These studies highlight altered metal 
homeostasis in the etiology of Parkinsonism. Interestingly, the overexpression of FPN in 
our pdr-1 mutants altered not only Mn, but Fe and Cu levels to a greater extent. We 
were not surprised to observe a treatment effect for Mn, as this was the only exogenous 
treatment administered to the nematodes. However, we did expect to see a greater 
decrease in Mn concentrations. It may be possible that currently unidentified Mn 
importers or exporters in C. elegans may be compensating to prevent the expected 
rescue of Mn accumulation. For example, there may be additional exporters that share 
similarities with the newly established cell surface Mn exporter SLC30A10, which does 
not have any C. elegans homologs. It is also possible that FPN’s affinity for Fe is 
greater than that of Mn, as the differential binding affinities have yet to be determined. 
Moreover, as FPN has not been shown to export Cu, the decrease in Cu levels may be 
a secondary effect of lowered intracellular Fe due to increased Fe efflux. Fe-deficiency 
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anemia has been associated with copper deficiencies, though the mechanism remains 
unknown321, 322.  
In addition to the well-characterized toxicity of Mn resulting in parkinsonian 
symptoms, enhanced iron accumulation in the SN is often seen in PD brains217, 323, with 
pharmacological Fe chelation showing potential therapeutic value324, 325. Moreover, Mn 
treatment has been recently shown to disrupt general metal homeostasis in WT C. 
elegans, with excess Mn resulting in altered Fe and Cu levels326. Though the authors of 
this study used slightly higher Mn concentrations (10-30 mM) than the present study, 
this was most likely due to the use of older worms treated for 24 hours, rather than 
larval stage worms acutely treated for 30 minutes. However, as their lowest dose (10 
mM) is within the range of the doses used in the present study, similar findings were 
seen with higher Mn concentrations (30 mM) corresponding with comparatively lower Fe 
and Cu levels overall326. The results in the present study provide further support of the 
interplay between metals, as exogenous Mn treatment results in the alteration of 
endogenous metal concentrations that may alter vital downstream processes. It is 
possible that the combined effects of decreased Fe and Cu levels, rather than the 
moderate to slight decrease in Mn levels, results in the amelioration of the pdr-1 KO 
phenotypes (Fig 15).  
Moreover, the recently discovered role of parkin as a mediator of mitophagy has 
introduced the potential significance of mitochondrial integrity in Parkinsonism327; loss of 
parkin could result in the accumulation of defective mitochondria to increase cellular 
oxidative stress. This could explain the significant increase in relative mtDNA copy 
number in pdr-1 KO animals as a measure that could equate with increased 
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mitochondrial mass in pdr-1 KOs. These data corresponds with our previously published 
findings that pdr-1 KOs exhibit significantly increased RONS levels. Notably, it seems 
controversial in the literature whether increased mtDNA copy number is protective or 
damaging in degenerative processes328, 329. However, increased mtDNA copy number 
has been associated with aging, as well as a response to increased oxidative stress318. 
Therefore, the increased copy number may also be in response to increased oxidative 
stress from enhanced Mn accumulation to compensate for damaged mitochondria. This 
may be especially true due to the preferential accumulation of Mn in mitochondria159. 
Consequently, the beneficial alterations in Mn, Fe and Cu in pdr-1 KO;fpn-1.1 OVR 
animals would then help to reverse this effect by decreasing metal-induced oxidative 
stress. Additionally, while the increase in the antioxidant GSH in pdr-1 KO;fpn-1.1 OVR 
animals vs. pdr-1 KO animals is moderate, it reaches trend-level significance. This may 
represent an improvement in the overall handling oxidative stress. It has been 
previously shown that neurons treated with increasing Fe concentrations show depletion 
in GSH content330. This is similar to the elevation in GSH content of pdr-1 KO;fpn-1.1 
OVR animals that also exhibit decreased Fe accumulation. However, we are limited in 
the present study, as we have been unsuccessful in using the microplate assay format 
to measure both GSSG and GSH. While pdr-1 KO;fpn-1.1 OVR and pdr-1 KO animals 
show no difference in gcs-1 (homolog for the glutamate-cysteine ligase responsible for 
catalysing GSH synthesis) mRNA expression (data not shown), future studies should be 
done to determine whether this change in GSH is due to more reduced vs. oxidized 
forms of GSH.  
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Finally, we previously reported that pdr-1 KO animals show an exacerbation of 
DAergic neurodegeneration compared to WT animals246. Currently, conflicting findings 
exist on the effects of Mn on DAergic neurodegeneration in C. elegans260, 326. However, 
this may be due to differences in treatment paradigms and doses. Additionally, 
fluorescence microscopy is a common technique to assess degeneration; however, 
microscopy for GFP visualization remains a mostly qualitative readout of cell death. 
Accordingly, we focused on an output parameter of an intact DAergic system by 
assaying a DA-dependent behavioural measure. The basal slowing response (BSR) is a 
well-known feeding response that requires DA and affects mechanosensation to 
properly recognize food sources (bacteria) in C. elegans228. Similar to our previous 
results, Mn treatment itself in WT animals did not result in a statistically significant 
decrease in BSR, though a slight decline was apparent. However, while pdr-1 KOs 
show impairment in this response, the rescue of BSR deficits by pdr-1 KO;fpn-1.1 OVR 
animals normalizes to the WT response. These data suggest that the overexpression of 
FPN normalizes DAergic integrity in the background of pdr-1 loss. The effect of Mn on 
BSR in pdr-1 KO and pdr-1 KO;fpn-1.1 OVR animals is negligible. This may be due to 
the complete loss of pdr-1 resulting in a “ceiling effect,” such that the addition of Mn 
exposure does not further exacerbate the basal differences. However, the BSR in pdr-1 
KO;fpn-1.1 OVR animals fully normalizes to WT levels upon treatment.  
Notably, we cannot relate the improvement in BSR to the improved survival of 
pdr-1 KO;fpn-1.1 OVR animals, as it has been previously reported that ablation of 
DAergic neurons in nematodes does not affect overall survival230. However, the 
relationship between metals and dopamine toxicity is well known. Dopamine itself is a 
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strong oxidant that can undergo an auto-oxidation process to produce highly damaging 
intermediates, which makes a strong argument for the vulnerability of DA-specific brain 
areas to toxins and other oxidants331. Mn has been shown to catalyse dopamine 
oxidation332, while Fe has been shown to specifically bind neuromelanin found in 
DAergic neurons333. Thus, the pdr-1 KO; fpn-1.1 OVR animals may show improvement 
in the DA-dependent BSR due to the lower bioavailability of Mn, Fe and Cu (Fig 15) that 
would otherwise participate in directly enhancing DA oxidation and/or indirectly 
producing damaging free radicals in an already susceptible cell type.  
 
 
Conclusions 
In conclusion, the present study provides further support for altered metal 
homeostasis as a critical component of PD pathophysiology. Using the genetically 
tractable C. elegans system, we show a novel role of pdr-1/parkin in modulating metal 
homeostasis following an acute Mn exposure by influencing metal efflux. Though 
human mutations in FPN have not yet been associated with PD, our findings 
demonstrate the importance and specificity of PD genetics (e.g. loss of pdr-1/parkin) in 
interacting with environmental factors to exacerbate physiological processes that may 
lead to cell death. Future studies should focus on potential therapeutic routes that help 
understand the interplay between pdr-1/parkin-mediated mitochondrial dynamics and 
enhanced efflux of redox-active metals like Mn, Fe and Cu as a strategy against Mn-
induced Parkinsonism.  
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CHAPTER IV 
 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
 
  
In summary, the data presented in this thesis support the hypothesis that loss of 
function of early-onset PD disease genes, namely pdr-1/parkin and djr-1.1/dj1, results in 
increased vulnerability to Mn toxicity in C. elegans, as evidenced by enhanced Mn 
accumulation and oxidative stress in these backgrounds. Our findings further support 
the hypothesis that WT αS may have protective qualities, as its expression in the 
background of pdr-1 and djr-1.1 loss ameliorates Mn toxicity by reducing Mn levels and 
RONS production. Though WT αS rescues DAergic neurodegeneration in pdr-1 KO 
animals that also exhibit increased dat-1 mRNA, it does not in djr-1.1 KO animals that 
show decreased dat-1 mRNA. These findings indirectly support the role of extracellular 
dopamine in exacerbating Mn toxicity.  Furthermore, our results show that pdr-1 loss 
confers the highest vulnerability to Mn-induced lethality, concurrent with the highest Mn 
accumulation. We show evidence of decreased fpn-1.1 mRNA expression in animals 
lacking pdr-1, with no change in expression of Mn importer genes, suggesting that Mn 
export, rather than import, is altered in these animals. Moreover, the overexpression of 
fpn-1.1 in the background of pdr-1 loss rescues toxic metal accumulation that 
concurrently improves mitochondrial and DAergic integrity. 
An interesting phenomenon in Chapter 2 revolves around DAergic-specific 
expression of human αS driving global changes in Mn accumulation, considering we do 
not yet have the technical skills in quantifying metal content within neurons specifically. 
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One possibility for this finding is following the theory that the progressive nature of PD 
may be due to αS propagation from one brain region to another. The spread of αS was 
first identified in previous clinical studies, where patients suffering from PD received 
transplants of nigral embryonic DAergic neurons into their striatum. More than a decade 
after surgery, αS- and ubiquitin-containing Lewy bodies, as well as reduced 
immunostaining for DAT, were present in the grafted neurons334, 335. Researchers also 
believe that this phenomenon may help explain the selectivity of DAergic neurons in PD. 
as dopamine itself has been shown to enhance the formation of non-fibrillar αS 
oligomers in intracellular vesicles. Increased cystolic DA levels using L-DOPA treatment 
subsequently results in secretion of αS oligomers into the media336. Moreover, inhibition 
of the autophagy/lysosome pathway results in increased intercellular transfer of αS from 
donor neurons expressing αS to recipient cells, which then exhibit enhanced apoptotic 
cell death337. This is of particular interest in terms of Parkin’s involvement in mitophagic 
processes that utilize this pathway, as well as its general role in protein clearance. In 
fact, a recent study provides evidence that mice lacking parkin show increased transfer 
of αS from the brain to the blood, with increased Parkin ubiquitination/activity aiding in 
αS clearance and turnover. Thus, the authors conclude that PD patients suffering from 
parkin mutations may not characteristically exhibit Lewy bodies due to the loss of αS 
sequestration through autophagic elimination338.  
The connection between environmental toxicants and αS aggregation has been 
well established. Uversky et al. first showed that Mn2+ could accelerate the rate of αS 
fibril formation254, with a later study finding that αS selectively exacerbates Mn2+ (and 
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not Fe2+)-induced cell death in DAergic cells expressing DAT339. More recent evidence 
in primates has confirmed that Mn exposure can induce αS aggregation in neurons of 
the frontal cortex213. However, the link between toxicants and transneuronal αS 
transport has only recently been examined. For example, exposure to rotenone in mice 
results in increased release of αS from enteric neurons into the surrounding media, with 
a higher amount of αS found in exosomes. These studies also utilized co-cultures to 
find that the rotenone-induced, released αS could be taken up into TH+ neurons and 
retrogradely transported into the soma294. Collectively, such evidence indicates the 
ability of αS to propagate from one cell to the other, though the mode of transport may 
not be well understood yet.  
Our findings of global Mn-induced changes that are modulated by DA-specific αS 
expression may support this theory of αS propagation in C. elegans. In particular, the 
protective effects of WT αS in reducing whole-worm Mn toxicity and accumulation could 
be due to the spread of αS from DAergic neurons to neighboring cells to propagate its 
metal- quenching qualities. While this has yet to be determined, studies have found 
copper-and iron-binding sites, as well as its ability to alter Fe oxidation states291, 340. As 
these metal ions have been shown to share transport mechanisms and roles as 
cofactors, it may be possible for αS to also bind Mn. Future studies should examine its 
potential secretion in the context of a pdr-1 mutant background, as our studies do not 
examine whether intracellular αS aggregation upon WT expression in this background is 
altered. It is also important to note that our studies did not investigate the effects of the 
aforementioned mutant forms of αS, and whether the opposite outcomes would be seen 
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(i.e., lack of a rescue of Mn accumulation and toxicity).  Since αS is not endogenously 
expressed in C. elegans and has not been shown to be secreted in this system, 
however, a more likely possibility behind the global alterations may revolve around the 
direct control and influence of αS-expressing DAergic neurons on other cells. In fact, 
dopamine has been shown to act extrasynaptically in C. elegans; the DA receptors 
DOP-1 and DOP-3 are expressed on ventral motor cord neurons that are not 
postsynaptic to DAergic neurons341. Thus, I hypothesize that humoral DA secretions342 
could result in the control of any cell expressing a DA receptor, potentially including 
neurons in the gut where Mn absorption is greatly influenced.  
A major question left unanswered in Chapter 3 is how the loss of pdr-1 in C. 
elegans results in altered fpn-1.1 expression. As worms conserve PDR-1 ligase activity, 
one would expect that the loss of pdr-1 would result in the lack of FPN degradation, if 
FPN were a direct target of PDR-1. While it would have been beneficial to test this idea 
using Western blot techniques to assess FPN protein expression, the lack of 
commercially available C. elegans-specific antibodies made this difficult. Regardless, 
qRT-PCR methods revealed the opposite effect of decreased fpn-1.1 mRNA levels in 
pdr-1 KO animals. Although it is possible that the difference in mRNA levels may not 
correspond with protein expression, one could hypothesize that the fpn-1.1 
downregulation may be an indirect effect of pdr-1 loss. As most E3 ubiquitin ligases 
have several target substrates, it may be possible that one of Parkin’s targets is able to 
regulate FPN expression. The FPN system in C. elegans has not been extensively 
studied enough to fully understand how the exporters may be regulated in nematodes. 
In mammalian systems, however, some regulatory mechanisms have been investigated, 
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with the most prominent one being hepcidin, a peptide hormone. Hepcidin binds and 
inhibits FPN to control dietary iron absorption in mammals. However, the C. elegans 
genome does not contain any hepcidin-like genes.  
There are other hepcidin-independent regulatory mechanisms to control FPN 
expression. These include the hypoxia-inducible factor 1 (HIF-1), a member of a 
transcription factor protein family that is stabilized under hypoxic conditions to promote 
upregulation of genes that foster survival in low-oxygen states. The C. elegans genome 
encodes a single homolog for HIF-1 (hif-1) that can modulate longevity in worms343.  
While evidence in C. elegans has found hif-1 to act as a negative regulator of ferritin 
(ftn-1 and ftn-2) transcription344, no studies have yet examined whether the HIF-1-
mediated control of FPN is conserved in nematodes. Some studies have also 
connected the Alzheimer’s disease-associated amyloid precursor protein (APP) as 
another modifier of FPN function. Controversial findings suggest that APP may have 
ferroxidase activity345, 346, with recent evidence indicating that endogenous APP may 
help stabilize cell-surface expression of FPN346 to modulate iron export. The precise 
mechanism of the APP-FPN interaction, however, remains unclear. In C. elegans, it 
would be interesting to evaluate the expression of APL-1, the worm homolog of APP347, 
in the background of pdr-1 loss to determine whether altered APL-1 levels may be 
associated with FPN-1.1 downregulation; likewise, assessing pdr-1 expression in the 
background of apl-1 loss may also aid in further understanding this putative interaction.  
 Another potential intermediary of pdr-1-mediated fpn1 regulation is Nrf2, the 
master regulator of neuroprotective antioxidant transcriptional responses.  Activation of 
this transcription factor has been show to upregulate fpn-1 mRNA in human and mice 
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macrophages, with microarray analysis confirming FPN1 to be an Nrf2 target gene. skn-
1 is the C. elegans homolog for the nrf2 gene. While we show a slight increase in skn-1 
mRNA expression in pdr-1 KOs (Fig 7A) vs. WT animals, it remained statistically 
insignificant. Our studies do not address whether SKN-1 activation and/or activity itself 
is altered in the background of pdr-1 loss, which would provide a more mechanistic view 
at whether Nrf2-mediated regulation of FPN expression is conserved in C. elegans. 
Future studies should consider crossing worms containing a SKN-1 translational fusion 
reporter (SKN-1::GFP) with the pdr-1 KO and pdr-1 KO;fpn-1.1 OVR animals to assess 
nuclear translocation of SKN-1 as an indication of its activation. It may also be 
worthwhile to assess the transcription of SKN-1’s downstream targets, such as gst-4, in 
the background of pdr-1 KO and pdr-1 KO;fpn-1.1 OVR animals.  
 DJ-1 has been shown to stabilize Nrf2 by preventing association with its inhibitor 
protein Keap1106. If the loss of parkin results in decreased DJ-1, as seen in neurons272, 
loss of Nrf2 stabilization could then result in the decreased fpn-1.1 expression seen in 
pdr-1 KOs (Fig 10D). However, other evidence in neurons has found that activation of 
the Nrf2 pathway occurs in a DJ-1-independent manner348. Nonetheless, future studies 
should examine the potential role of Nrf2 in the Parkin-FPN relationship, as oxidative 
stress plays such a significant role in both Parkinsonism and metal dyshomeostasis. 
While the studies presented in this thesis do not identify what this intermediary may be, 
ongoing efforts include microarray analysis that may reveal new targets of pdr-1, which 
could subsequently regulate fpn-1.1 expression in C. elegans.  
A recurring issue throughout the studies presented in this thesis is the lack of a 
direct effect of Mn on any of the outcomes tested. While Mn treatment shows a dose-
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dependent effect on lethality and Mn accumulation in WT worms, most of the outcomes 
do not show significant differences between untreated and treated WT animals. This 
may be due to the treatment paradigm used, with the possibility that an acute, 30-
minute treatment in L1 larval worms is not sufficient to cause significant changes. This 
may also be compounded by the fact that the extracts for most of the biochemical 
techniques presented were isolated directly after treatment. It would be interesting to 
determine whether a longer exposure time and/or longer time post-exposure for extract 
preparation would produce different phenotypic outcomes than what is presented.  
Moreover, the thick cuticle barrier has also posed several technical problems, 
most notably, the necessity of administering high Mn concentrations (in the millimolar 
range) to produce any effects. While ICP-MS methodology has been extremely valuable 
in revealing variable intraworm metal accumulation, the lack of clear, quantitative 
methods to assess metal uptake itself has hindered full understanding of Mn 
homeostasis in pdr-1 KO animals. The LA-ICP-MS method at least provided 
confirmation that the metal levels revealed by ICP-MS did have any contributions from 
unwashed metals stuck to the outside cuticle (Fig 5E). However, this method still 
remains qualitative in nature, with ongoing efforts to determine how to quantitatively 
analyze these results. We have also attempted to optimize the cellular Fura-2 
manganese extraction assay (CFMEA) established by our colleagues349 for C. elegans, 
but were unsuccessful. Future studies should consider radiolabeled substrate (or 
fluorescence) uptake assays to determine whether Mn transport dynamics are altered. 
Another interesting finding in Chapter III points to a much higher overall concentration of 
Mn in worms compared to Fe. Typically, the reverse is the case in other systems. 
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Though previously published findings from our laboratory using GFAAS show Fe to be 
at a higher level than Mn in WT worms, this may be due to differences in the methods 
used (ICP-MS/MS vs. GFAAS) and the resulting sensitivities. The GFAAS findings were 
also expressed as metal content per 1000 worms, which is both a significantly smaller 
sample size compared to the 50,000-worm samples we used for ICP-MS/MS, and lacks 
the accuracy of protein normalization. However, a potential explanation is the lack of a 
circulatory system in worms, as most of Fe in mammalian systems is primarily required 
for hemoglobin in red blood cells350.  
Additionally, assessment of mitochondrial dynamics and oxidative stress proved 
to be difficult in C. elegans during the course of this project. The use of the DCF dye in 
Chapter 2 to measure RONS production was optimized from previous techniques used 
in the laboratory237 to “pre-treat” worms with the dye before MnCl2 exposure, in order to 
better catch the immediate effects of Mn treatment.  While we were able to obtain robust 
readings of RONS production through this method, the use of this dye was based on its 
frequent use in the literature. However, this assay is not thorough in its detection 
abilities, as it cannot measure H2O2, along with the caveat of potential dye leakage that 
we may not have been aware of351. Future investigations using this dye in C. elegans 
should consider fluorescence microscopy to visualize dye loading within worms. 
Additionally, the contribution of RONS specifically from the mitochondria vs. total 
cellular RONS is not distinguished using DCF. Future experiments in Mn-treated worms 
should consider the use of a tool like the MitoSOX dye, which is rapidly oxidized by 
superoxide in mitochondria, and not by other forms of RONS, and can be assessed by 
its fluorescence. Moreover, another technical issue we encountered in assessing 
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oxidative stress was through the optimization of the cellular GSH recycling assay. 
Unfortunately, we were unable to measure oxidized GSH (GSSG) from the worms, 
leaving the assay to only dictate total GSH levels. While this can still be considered a 
readout of antioxidant response, it would be beneficial to utilize a method like HPLC to 
measure both GSH and GSSG for a fuller understanding of increased oxidative stress. 
We also attempted to assess mitochondrial bioenergetics using the Seahorse 
Biosciences Extracellular Flux Analyzer, which provides oxygen consumption rates 
following administration of various mitochondrial toxins. While the use of this machine to 
assess a variety of endpoints (e.g., basal respiration, ATP production, proton leakage) 
at once is attractive, the high costs associated with supplies and use of the equipment 
limited the amount of trials necessary to optimize this system for C. elegans. We 
attempted to vary the conditions of the Seahorse experimental paradigm from the 
original protocol for cells, but the injection times and concentrations of the mitochondrial 
toxins used (oligomycin, FCCP and rotenone), may not have been sufficient for the 
toxins to properly enter and accordingly affect the worms. Therefore, we could only rely 
on the basal respiration endpoint measured by the machine prior to the injection of 
mitochondrial toxins. Basal respiration was slightly decreased in pdr-1 KO’s compared 
to WT worms, with the pdr-1 KO;fpn-1.1 OVR animals showing even more of a 
decrease (trend level, p=0.0738, Supplementary Figure 1). However, these changes 
were slight and not significant. Though the trend for a lack of rescue by pdr-1 KO;fpn-
1.1 OVR animals is unexpected, we are not confident in these results truly reflecting the 
basal state of the worms, as this assay has not been used extensively in worms by 
other groups. However, if this were to be true, perhaps the rescue seen in pdr-1 KO;fpn-
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1.1 OVR animals is independent of changes in mitochondrial respiration. Future 
experiments must fully optimize the drug concentrations and injection times of the 
Seahorse mitochondrial stress test in order to correctly assess the other parameters of 
mitochondrial bioenergetics.  
Furthermore, the roles of Parkin and PINK1 as mediators of mitochondrial 
dynamics have not yet been extensively examined in C. elegans. This may be partially 
due to technical challenges with this model system. While we considered mtDNA copy 
number as a correlate of mitochondrial mass, we understand that this is not the most 
direct or comprehensive strategy in examining mitochondrial integrity. In terms of 
Parkin’s role in mitochondrial turnover, future experiments should consider adding a 
combination of techniques that assess both total mitochondrial mass, and the amount of 
that mass undergoing stress, thereby capturing the direct effects of pdr-1 loss and Mn 
exposure on mitochondrial dynamics. For example, mutilabeling using the mitochondrial 
dye MitoTracker Green, which labels all mitochondria independent of the membrane 
potential, in combination with the dye MitoTracker Red CMXRos, which is dependent on 
the membrane potential, can provide a ratio of red to green representing changes in 
mitochondrial membrane potential that is normalized to any changes in mitochondrial 
abundance. This could be combined with the use of the TMRE (tetramethylrhodamine, 
ethyl ester) dye in worms, which only accumulates in active mitochondria, with 
damaged, depolarized mitochondria unable to take up the dye. Using a combination of 
these methods (via fluorescence microscopy and/or flow cytometry), in addition to the 
qPCR-based method of mtDNA detection, would paint a more accurate picture of direct 
changes in mitochondrial dynamics.  
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Lastly, an accurate model of PD should reflect the signature DAergic 
neurodegeneration associated with the disease. Consequently, previous members of 
the laboratory have published findings that Mn selectively induces DAergic 
neurodegeneration in WT C. elegans260. However, I, along with other past and current 
members of the laboratory have not been able to reproduce these findings since that 
point, despite using the same treatment paradigm and imaging techniques. 
Interestingly, other groups have also struggled to reproduce the drastic degeneration 
seen in the published confocal fluorescent images. We attempted to formulate a new 
scoring method that considers all aspects of degeneration (shrunken soma, blebbing, 
etc) that may not have been considered previously, but still did not notice a drastic 
effect of Mn on DAergic neurons in WT animals (Figure 8). However, this may be even 
more indicative of Mn’s role as an environmental risk factor, with Mn accumulation, 
overall metal dyshomeostasis and oxidative stress preceding any overt degeneration. 
Though we cannot reproduce the GFP signal changes published by Benedetto and 
colleagues260, it is important to note that loss of the GFP signal in worms containing the 
pdat-1GFP trasngene is not necessarily a true reflection of degeneration. Fluorescence 
microscopy remains a qualitative assessment, as GFP signal may be lost, while cell 
death may not have truly occurred. According to personal communications with various 
members of the C. elegans community, there is a consensus that accurate analysis of 
neurodegeneration outside of fluorescent visualization is lacking in this system. For this 
reason, the behavioral approach was viewed as an output parameter of DAergic system 
integrity.  Another way to tackle this obstacle is to biochemically measure differences in 
dopamine levels. Ongoing efforts include the establishment of a liquid chromatography 
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mass spectrometry (LC-MS) method with our collaborators in Germany to measure 
worm DA levels for a more quantitative assessment of damage to the DAergic system. 
In conclusion, these studies collectively support the role of impaired metal 
homeostasis as a consequence of genetic mutations associated with early-onset PD, as 
well as the “multiple-hit” model signifying the distinctive roles of genetic risk factors in 
increasing vulnerability to toxin-mediated cell death. Furthermore, these findings provide 
a foundation for future studies on the interplay between WT αS neuroprotection, pdr-1-
mediated mitochondrial dynamics and enhanced metal efflux as therapeutic strategies 
against Mn-induced Parkinsonism.  
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SUPPLEMENTARY TABLES AND FIGURES 
 
Table 1. Conditions for ICP-MS/MS (Agilent 8800 ICP-QQQ) 
Power  1550 W  
Plasma gas 15 L/min 
Carrier gas 1.0 L/min 
Auxiliary gas 0.9 L/min 
Scan mode single quad 
Q1 ion guide 
Collision cell gas flow He: 4.5 mL/min (purity: > 99.999 %)  
H2: 0.5 mL/min (purity: > 99.999 %) 
Q2 55Mn, 103Rh (ISTD) 
Integration Time 1.0 s 
Replicates 5 
 
Table 2. Conditions for ICP-MS (ICAP Qc, Thermo Fisher Scientific) 
Power  1550 W  
Nebulizer Flow  780 mL/min 
Cool Flow  14.0 L/min 
Auxilliary Flow  500 mL/min 
Measurement mode KEDS 
Cell gas flow 4.6 mL/min 
 
Table 3. Conditions for LA (LSX213G2+, CETAC Technologies) 
Repetition frequency  20 Hz 
Spot diameter 4 µm 
Scan rate 4 µm/s 
He-flow 1 500 mL/min 
He-flow 2 300 mL/min 
Additional Ar-flow 400 mL/min 
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Supplementary Figure 1. Decreased basal respiration in pdr-1 mutants 
that is not rescued by fpn-1.1 overexpression. Statistical analysis by two-way 
ANOVA: interaction, ns; genotype, p=0.0738 (trend level); concentration, ns.  
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